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Background: Chronic obstructive pulmonary disease is a major contributor to morbidity, mortality and
health service costs but is vastly underdiagnosed. Evidence on screening and how best to approach this
is not clear. There are also uncertainties around the natural history (prognosis) of chronic obstructive
pulmonary disease and how it impacts on work performance.
Objectives: Work package 1: to evaluate alternative methods of screening for undiagnosed chronic
obstructive pulmonary disease in primary care, with clinical effectiveness and cost-effectiveness analyses
and an economic model of a routine screening programme.Work package 2: to recruit a primary care
chronic obstructive pulmonary disease cohort, develop a prognostic model [Birmingham Lung Improvement
StudieS (BLISS)] to predict risk of respiratory hospital admissions, validate an existing model to predict
mortality risk, address some uncertainties about natural history and explore the potential for a home
exercise intervention. Work package 3: to identify which factors are associated with employment,
absenteeism, presenteeism (working while unwell) and evaluate the feasibility of offering formal
occupational health assessment to improve work performance.
Design: Work package 1: a cluster randomised controlled trial with household-level randomised
comparison of two alternative case-finding approaches in the intervention arm. Work package 2:
cohort study – focus groups. Work package 3: subcohort – feasibility study.
Setting: Primary care settings in West Midlands, UK.
Participants: Work package 1: 74,818 people who have smoked aged 40–79 years without a
previous chronic obstructive pulmonary disease diagnosis from 54 general practices. Work package 2:
741 patients with previously diagnosed chronic obstructive pulmonary disease from 71 practices and
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participants from the work package 1 randomised controlled trial. Twenty-six patients took part in
focus groups. Work package 3: occupational subcohort with 248 patients in paid employment at
baseline. Thirty-five patients took part in an occupational health intervention feasibility study.
Interventions: Work package 1: targeted case-finding – symptom screening questionnaire, administered
opportunistically or additionally by post, followed by diagnostic post-bronchodilator spirometry. The
comparator was routine care. Work package 2: twenty-three candidate variables selected from literature
and expert reviews. Work package 3: sociodemographic, clinical and occupational characteristics;
occupational health assessment and recommendations.
Main outcome measures: Work package 1: yield (screen-detected chronic obstructive pulmonary
disease) and cost-effectiveness of case-finding; effectiveness of screening on respiratory hospitalisation
and mortality after approximately 4 years. Work package 2: respiratory hospitalisation within 2 years,
and barriers to and facilitators of physical activity. Work package 3: work performance – feasibility and
acceptability of the occupational health intervention and study processes.
Results: Work package 1: targeted case-finding resulted in greater yield of previously undiagnosed
chronic obstructive pulmonary disease than routine care at 1 year [n = 1278 (4%) vs. n = 337 (1%),
respectively; adjusted odds ratio 7.45, 95% confidence interval 4.80 to 11.55], and a model-based
estimate of a regular screening programme suggested an incremental cost-effectiveness ratio of
£16,596 per additional quality-adjusted life-year gained. However, long-term follow-up of the trial
showed that at ≈4 years there was no clear evidence that case-finding, compared with routine practice,
was effective in reducing respiratory admissions (adjusted hazard ratio 1.04, 95% confidence interval
0.73 to1.47) or mortality (hazard ratio 1.15, 95% confidence interval 0.82 to 1.61). Work package 2:
2305 patients, comprising 1564 with previously diagnosed chronic obstructive pulmonary disease and
741 work package 1 participants (330 with and 411 without obstruction), were recruited. The BLISS
prognostic model among cohort participants with confirmed airflow obstruction (n = 1894) included
6 of 23 candidate variables (i.e. age, Chronic Obstructive Pulmonary Disease Assessment Test score,
12-month respiratory admissions, body mass index, diabetes and forced expiratory volume in 1 second
percentage predicted). After internal validation and adjustment (uniform shrinkage factor 0.87,
95% confidence interval 0.72 to 1.02), the model discriminated well in predicting 2-year respiratory
hospital admissions (c-statistic 0.75, 95% confidence interval 0.72 to 0.79). In focus groups, physical activity
engagement was related to self-efficacy and symptom severity. Work package 3: in the occupational
subcohort, increasing dyspnoea and exposure to inhaled irritants were associated with lower work
productivity at baseline. Longitudinally, increasing exacerbations and worsening symptoms, but not a
decline in airflow obstruction, were associated with absenteeism and presenteeism. The acceptability
of the occupational health intervention was low, leading to low uptake and low implementation of
recommendations and making a full trial unfeasible.
Limitations: Work package 1: even with the most intensive approach, only 38% of patients responded
to the case-finding invitation. Management of case-found patients with chronic obstructive pulmonary
disease in primary care was generally poor, limiting interpretation of the long-term effectiveness of
case-finding on clinical outcomes. Work package 2: the components of the BLISS model may not always
be routinely available and calculation of the score requires a computerised system. Work package 3:
relatively few cohort participants were in paid employment at baseline, limiting the interpretation of
predictors of lower work productivity.
Conclusions: This programme has addressed some of the major uncertainties around screening
for undiagnosed chronic obstructive pulmonary disease and has resulted in the development of a
novel, accurate model for predicting respiratory hospitalisation in people with chronic obstructive
pulmonary disease and the inception of a primary care chronic obstructive pulmonary disease cohort
for longer-term follow-up. We have also identified factors that may affect work productivity in people
with chronic obstructive pulmonary disease as potential targets for future intervention.
ABSTRACT
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Future work: We plan to obtain data for longer-term follow-up of trial participants at 10 years.
The BLISS model needs to be externally validated. Our primary care chronic obstructive pulmonary
disease cohort is a unique resource for addressing further questions to better understand the prognosis
of chronic obstructive pulmonary disease.
Trial registration: Current Controlled Trials ISRCTN14930255.
Funding: This project was funded by the National Institute for Health Research (NIHR) Programme
Grants for Applied Research programme and will be published in full in Programme Grants for Applied
Research; Vol. 9, No. 13. See the NIHR Journals Library website for further project information.
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Chronic obstructive pulmonary disease is an important lung disease, affecting around 10% of adultsworldwide. Each year in the UK, it accounts for 1.4 million general practitioner consultations,
1 million hospital bed-days and around 24 million lost working days. However, at least half of those
with chronic obstructive pulmonary disease are unaware of their diagnosis and these people may not
receive early treatment. Before our research there was uncertainty about (1) how to best identify
these missing patients, (2) whether or not early identification would benefit patients, (3) how chronic
obstructive pulmonary disease progresses, (4) what characteristics (other than smoking) affect risk of
hospital admission or early death and (5) what aspects influence ability to work in people with chronic
obstructive pulmonary disease.
We found that if general practitioners offered screening to smokers aged over 40 years then they could
identify seven times as many people with chronic obstructive pulmonary disease than they do currently.
However, although these patients could potentially benefit from therapies, the health system was not
set up to support doctors to provide all the recommended treatments. Our economic model suggested
that screening was worthwhile for detecting undiagnosed chronic obstructive pulmonary disease.
However, after 4 years we found that screening did not reduce the risk of hospital admissions or death.
We also followed up around 2000 people with chronic obstructive pulmonary disease to see which
features were linked with the risk of hospital admission with a lung problem. Through this we
developed a tool that could measure an individual’s chronic obstructive pulmonary disease severity.
This has the potential to allow doctors to make more appropriate patient management decisions, but it
needs more testing.
Finally, we examined which attributes (related to the patient, their lung problem or their workplace)
affected people’s ability to work. We found that people who are more breathless or exposed to inhaled
hazards may have poorer work performance. However, because few patients in the study were in paid
employment, we cannot draw firm conclusions.
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At least half of people with chronic obstructive pulmonary disease are undiagnosed, but the best
approach for identifying them is not established. Furthermore, screening is not recommended because
it is not yet known if it leads to clinical benefits.
There is increasing recognition that chronic obstructive pulmonary disease is heterogeneous, and,
although a number of prognostic models have been developed, most prognostic models include people
with more severe disease within secondary care. It is not known which combination of phenotypic
characteristics best predict prognosis in the larger primary care chronic obstructive pulmonary disease
population, particularly in relation to respiratory hospitalisations.
Effective treatment for those with mild chronic obstructive pulmonary disease is limited. Physical
activity promotion is a potential intervention, but its acceptability to primary care chronic obstructive
pulmonary disease patients is unknown.
A substantial proportion of chronic obstructive pulmonary disease patients are of working age. Although
there is some evidence that they have poorer employment history and work productivity, the main
factors that are associated with these outcomes have not to our knowledge been previously studied.
The aim of this programme was to address the above uncertainties.
Objectives
Work package 1
l Ascertain the clinical effectiveness and cost-effectiveness of targeted case-finding (opportunistic or
active) compared with routine care.
l Develop a Markov model to compare the cost-effectiveness of systematic case-finding with
current practice.
l Explore the views of patients and primary care staff on chronic obstructive pulmonary disease case-finding.
l Describe the clinical management of screen-detected chronic obstructive pulmonary disease
patients in primary care.
l Assess the long-term effectiveness of chronic obstructive pulmonary disease case-finding on
respiratory hospitalisations and mortality.
l Compare outcomes among screen-detected chronic obstructive pulmonary disease patients who
were adequately managed by their general practitioner with those among patients who were not.
Work package 2
l Recruit a primary care cohort of 2000 new and existing chronic obstructive pulmonary disease patients.
l Test the validity of existing chronic obstructive pulmonary disease prognostic models in a primary
care chronic obstructive pulmonary disease population.
l Develop a prognostic model (BLISS index) to predict respiratory hospitalisations suitable for a
primary care population.
l Explore the barriers to and facilitators of physical activity participation among people with chronic
obstructive pulmonary disease.
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Work package 3
l Examine factors associated with occupational performance [employment, absenteeism and
presenteeism (working while unwell)] among chronic obstructive pulmonary disease patients
of working age.
l Examine how disease progression is associated with occupational performance.
l Assess the feasibility of offering occupational health assessment with recommendations to people
with chronic obstructive pulmonary disease.
Methods
Work package 1: TargetCOPD cluster randomised controlled trial
Fifty-four general practices were randomly assigned to either targeted case-finding or routine care.
Eligible patients were people who had smoked, were aged 40–79 years and did not have a previous
chronic obstructive pulmonary disease diagnosis. Those in the targeted arm were further randomly
assigned to receive a symptom screening questionnaire either at any general practitioner visit
(opportunistic) or by post (active). Respondents reporting relevant respiratory symptoms were invited
for diagnostic post-bronchodilator spirometry.
Primary outcomes were percentage of the eligible population diagnosed with chronic obstructive
pulmonary disease within 1 year (yield) and cost per new chronic obstructive pulmonary disease
diagnosis using trial data.
At 4–5 years’ follow-up, data on mortality and hospitalisations were obtained from NHS Digital for
all eligible patients, and case-found chronic obstructive pulmonary disease patients were invited to
complete a health questionnaire to report on their health-related quality of life as well as treatments
received for chronic obstructive pulmonary disease. For case-found patients, we also obtained data
from electronic health records on whether or not they had been added to the practice’s Quality and
Outcomes Framework chronic obstructive pulmonary disease register within 12 months and whether
or not they had been prescribed a range of chronic obstructive pulmonary disease treatments.
Cox proportional hazards models adjusted for potential confounding factors were used to model the
time to clinical outcomes (i.e. death, first respiratory hospital admission) in the intervention and routine
arms. Time to event was censored at death (for admission) or study end date if no event occurred.
For case-found patients, we used logistic and Poisson regression to compare mortality, hospitalisation
and health-related quality of life among those who were and those who were not added to the chronic
obstructive pulmonary disease register, adjusting for baseline values and relevant confounders.
Data from the trial and our cohort study (work package 2) as well as from the published literature
were used to develop a Markov decision-analytic model to compare the cost-effectiveness of a 3-yearly
case-finding programme aimed at people who have smoked aged > 50 years with current practice,
taking a health service perspective.
We interviewed patients who had been invited for screening and primary care staff in targeted
case-finding practices to explore their views on screening.
Work package 2: Birmingham primary care chronic obstructive pulmonary disease cohort
Patients aged ≥ 40 years with previously diagnosed chronic obstructive pulmonary disease from
71 practices, as well as those reporting chronic respiratory symptoms as part of the TargetCOPD trial,
were invited to join the cohort study. Participants underwent detailed baseline assessment, were
followed up with 6-monthly questionnaires and underwent a final assessment at ≈3 years.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
Using data from those with chronic obstructive pulmonary disease in the cohort, linked to mortality
data obtained from NHS Digital, we sought to validate the ADO (age, dyspnoea, airflow obstruction)
prognostic score. This was shown to be the most discriminatory among current indices in predicting
mortality in a recent review. Discrimination was calculated using the c-statistic. Calibration was
assessed by comparing predicted with actual probability of mortality.
To develop a new index to predict respiratory admissions, we considered 23 candidate variables identified
from the literature and by a clinician stakeholder group. Self-reported and clinical data from cohort
patients were linked to hospitalisation data obtained through NHS Digital. The primary outcome was
the record of at least one respiratory admission within 2 years of cohort entry. The model was developed
using backward elimination (p < 0.157 for retention). Fractional polynomials were considered and multiple
imputation using chained equations was used for missing data. Discrimination and calibration were
assessed. Bootstrapping was used for internal validation and the optimum-adjusted performance statistics
were estimated.
A purposive sample of 26 cohort patients with a range of chronic obstructive pulmonary disease severity
participated in one of four focus groups to explore perceived barriers to and facilitators of physical
activity engagement, using the social cognitive theory framework. Thematic analysis identified key
concepts related to the patients’ self-efficacy beliefs.
Work package 3: occupational performance and outcomes in chronic obstructive
pulmonary disease
Using baseline data of cohort participants who were of working age, we compared the sociodemographic,
clinical and occupational characteristics of people who were in paid employment with those of people
who were not. Among those in paid employment, we examined characteristics associated with
absenteeism (self-report over previous 12 months) and presenteeism (Stanford Presenteeism Scale).
Longitudinal multivariable regression analyses, adjusting for clinical, sociodemographic, occupational
and labour market factors among participants in paid employment, were conducted to examine the
effects of disease progression [forced expiratory volume in 1 second decline, respiratory hospitalisations
(exacerbations), increase in Medical Research Council dyspnoea score, worsening Chronic Obstructive
Pulmonary Disease Assessment Test score] on employment, absenteeism and presenteeism.
Cohort participants who were in paid employment at baseline were invited for a tailored occupational
health assessment to explore and identify workplace factors that might contribute to their work
performance and to recommend appropriate modifications. Participants’ self-management practices
were also assessed. Recommendations were sent to the participant and, with their permission, to their
general practitioner and employer. We examined acceptability and feasibility of the intervention.
Results
Work package 1
Effects of case-finding on yield
A total of 74,818 patients took part. Very few new cases of chronic obstructive pulmonary disease were
diagnosed in routine practice. The yield from targeted case-finding was significantly higher (adjusted
odds ratio 7.45, 95% confidence interval 4.80 to 11.55) and active case-finding was more clinically
effective (adjusted odds ratio 2.34, 95% confidence interval 2.06 to 2.66) and more cost-effective than
the opportunistic-only approach (£333 vs. £376 per case detected, respectively).
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Decision-analytic model of cost-effectiveness of case-finding
Our model predicted that the incremental cost-effectiveness ratio of a systematic 3-year case-finding
programme compared with routine care was £16,596 per additional quality-adjusted life-year gained if
assumptions hold, giving this a high probability of being cost-effective using the UK willingness-to-pay
threshold of £20,000 per quality-adjusted life-year.
Stakeholder views on case-finding
Both patients and primary care staff generally considered screening to be valuable. Patients highlighted
the presence of symptoms and convenience of the screening process as factors promoting screening
attendance. Better support from secondary care, an increase in specialist chronic obstructive pulmonary
disease nurses and better community respiratory service provision would support primary care staff in
undertaking case-finding. Patient barriers to screening attendance included psychological and practical
factors, such as time, availability and perceived lack of general practitioner time. Primary care staff had
concerns around lack of resource for increasing workload and potential harm from overdiagnosis.
Management of case-found patients
A year after case-finding, approximately one-fifth of case-found patients but > 90% of routinely
diagnosed patients had been added to a chronic obstructive pulmonary disease register. Patients who
had been added to a chronic obstructive pulmonary disease register were significantly more likely to
receive appropriate chronic obstructive pulmonary disease-related care (more than five items of clinical
assessment and/or management) than those who had not been added to a register. However, even among
those on the register, fewer than one-quarter of eligible patients had ever been referred to pulmonary
rehabilitation and a significant proportion of smokers had not received smoking cessation support.
Effectiveness of case-finding on clinical outcomes
Over a mean follow-up of 4.3 years, 4.8% (1557/32,743) of patients in the case-finding arm and
4.5% (1899/41,950) in the routine arm had a respiratory hospitalisation (adjusted hazard ratio
1.04, 95% confidence interval 0.73 to 1.47). The corresponding hazard ratio for mortality was 1.15
(95% confidence interval 0.82 to 1.61), suggesting that, overall, there was no significant difference
in risk of hospitalisation and mortality between case-found and routine care arms and there was no
noteworthy difference in outcomes between those in the two case-finding intervention arms. Among
the case-found patients, when comparing those who were and those who were not on the chronic
obstructive pulmonary disease register, there was no statistically significant difference in clinical
outcomes or in EuroQol-5 Dimensions scores, although the Chronic Obstructive Pulmonary Disease
Assessment Test score was higher in those on the chronic obstructive pulmonary disease register
(mean difference 2.317, 95% confidence interval 0.481 to 4.153), indicating greater impact of chronic
obstructive pulmonary disease on their health-related quality of life.
Work package 2
Birmingham chronic obstructive pulmonary disease cohort
Data on 2250 patients (97.8%) were available over 3 years. Six-monthly questionnaires were completed
by approximately two-thirds of patients. Over the period of follow-up (minimum 1.8 years, maximum
3.8 years), 382 patients (17%) had at least one respiratory hospital admission and 124 patients died.
Validation of age, dyspnoea, airflow obstruction prognostic score
Valid data were available for 1701 chronic obstructive pulmonary disease patients with airflow
obstruction (309 case-found patients). Age, dyspnoea, airflow obstruction prognostic scores
discriminated 3-year mortality accurately (c-statistic 0.73, 95% confidence interval 0.67 to 0.79),
with similar discriminatory ability for 2- and 1-year mortality (c-statistic 0.72, 95% confidence interval
0.67 to 0.77 and 0.73 and 95% confidence interval 0.66 to 0.80, respectively). However, there was
some overprediction, which was more pronounced at 1- and 2-year mortality time points (calibration
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slopes 0.96, 0.80 and 0.79 for 3- 2- and 1-year mortality, respectively) and in those with higher
baseline age, dyspnoea, airflow obstruction prognostic scores.
Development of the Birmingham Lung Improvement StudieS prognostic index
Among 1564 previously diagnosed and 330 case-found patients, 253 (13%) had a respiratory admission
within 2 years (367 had a respiratory admission over median follow-up of 3 years). Out of 23 candidate
variables, six were retained in the final developed model: age, Chronic Obstructive Pulmonary Disease
Assessment Test score, respiratory admissions in the previous 12 months, body mass index, diabetes
and forced expiratory volume in 1 second percentage predicted. After adjustment for optimism, the
primary model performed well in discriminating between those with and without 2-year respiratory
admissions (c-statistic 0.75, 95% confidence interval 0.72 to 0.79).
Barriers to and facilitators of physical activity engagement
Several barriers to and facilitators of engagement with physical activity, closely related to self-efficacy
beliefs and symptom severity, were identified. Barriers were health related, psychological, attitudinal
and motivational. Self-regulation (e.g. keeping a routine), self-efficacy (sense of achievement), enjoyment
and social aspects of physical activity motivated participation.
Work package 3
Factors associated with occupational outcomes
Among 608 cohort participants of working age, 248 (40.8%) were in paid employment. Older age
(odds ratio 0.28, 95% confidence interval 0.12 to 0.65), lower educational level (odds ratio 0.43, 95%
confidence interval 0.19 to 0.97), poorer BODE (body mass index, airflow obstruction, dyspnoea, and
exercise) prognostic score (odds ratio 0.10, 95% confidence interval 0.03 to 0.33) and history of high
occupational exposure to vapours, gases, dusts or fumes (odds ratio 0.32, 95% confidence interval 0.12
to 0.85) were associated with a lower probability of being employed. Of those in paid employment,
higher levels of dyspnoea were associated with both absenteeism and presenteeism (p-trend < 0.01).
Additionally, occupational vapours, gases, dusts or fumes exposure was associated with presenteeism
(p-trend < 0.01).
Follow-up data were available for 174 of those in paid employment at baseline. Over a mean follow-up
of 25.8 months, 144 (82.8%) participants remained employed. The point estimate suggested an inverse
association between increasing respiratory hospital admissions and probability of remaining in work
(odds ratio 0.32, 95% confidence interval 0.09 to 1.14; p = 0.08), although wide confidence intervals
suggest that further research is needed.
Prospective absenteeism data were available for 113 participants (mean follow-up of 19.5 months).
Worsening breathlessness (incidence rate ratio 3.06, 95% confidence interval 1.29 to 7.26; p = 0.01)
and increasing respiratory hospital admissions (incidence rate ratio 2.01, 95% confidence interval
1.09 to 3.69; p = 0.03) were associated with increased sickness absence. Follow-up presenteeism data
were available for 163 participants (86.2%), where 43 (26.4%) had worsening presenteeism. This was
significantly associated with worsening Chronic Obstructive Pulmonary Disease Assessment Test score
(odds ratio 5.74, 95% confidence interval 1.18 to 27.83; p = 0.03) and there was some evidence of
association with worsening dyspnoea.
Occupational health feasibility study
Only 35 (11.3%) of the eligible patients agreed to take part in the occupational health study. Of these,
80.0% received at least one occupational health recommendation and all received self-management
recommendations. However, only 37.3% of recommendations were reported as implementable. The
very low uptake rates for the intervention and low implementation of recommendations suggests that,
in its current format, the intervention is not feasible.
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Conclusions
Despite screening resulting in higher yield of undiagnosed cases of chronic obstructive pulmonary
disease and promising results from our health economic model, we did not find evidence of clinical
benefit at 4 years’ trial follow-up. The poor clinical management of chronic obstructive pulmonary
disease generally, and low addition of case-found patients to the practice chronic obstructive pulmonary
disease register, may explain the findings. The benefit of current treatments in case-found patients
remains unknown.
For a screening programme to be implemented and have high uptake, it is important to raise patient
awareness of chronic obstructive pulmonary disease risk factors and symptoms and provide training
and additional resources for primary care. In particular, it is important to ensure that management
pathways for diagnosed chronic obstructive pulmonary disease patients are optimised before further
cases are identified.
We have developed a new index, using data from people with chronic obstructive pulmonary disease in a
UK primary care setting, that has good discrimination performance in predicting respiratory hospitalisations.
This needs external validation and examination of its impact on care and outcomes. We confirmed
that the age, dyspnoea, airflow obstruction score is discriminatory for predicting mortality in a primary
care population.
Among people with chronic obstructive pulmonary disease who are of working age, having greater
breathlessness, a greater number of respiratory admissions and greater occupational exposure to
vapours, gases, dusts or fumes are associated with poorer work productivity. Although our occupational
health intervention was not feasible, modifiable workplace adaptations and self-management actions
were identified for almost all participants, suggesting possible benefit from such assessments in a
different context.
Recommendations for further research
l Development and evaluation of interventions to improve management of chronic obstructive
pulmonary disease in primary care, including pathways to manage case-found chronic obstructive
pulmonary disease.
l Evaluation of existing interventions in case-found chronic obstructive pulmonary disease.
l External validation of the BLISS index in new data.
l Evaluation of impact of using the BLISS index to guide patient management.
l Development and evaluation of interventions to reduce dyspnoea and vapours, gases, dusts or
fumes exposure on occupational outcomes in people with chronic obstructive pulmonary disease.
Trial registration
This trial is registered as ISRCTN14930255.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 9, No. 13. See the NIHR Journals Library website for further project information.
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Chronic obstructive pulmonary disease (COPD) is a chronic progressive respiratory condition with an
estimated worldwide prevalence of 9.21–11.7%2 in adults aged ≥ 30 years. However, at least half of
all people with COPD (depending on the diagnostic criteria) remain undiagnosed, representing a large
number with potentially unmet need.3,4 COPD is defined by the presence of airflow obstruction among
those with relevant risk factors but there is increasing recognition that the disease is heterogeneous,
with different causative factors, phenotypic characteristics and varying prognosis.5,6 A substantial
proportion of those with COPD are of working age, and there is some evidence that they have poorer
employment history,7 higher rates of sickness absence8 and poorer work performance [because of
presenteeism (working while unwell)]9 compared with the general population. In the UK, COPD is
estimated to cost the NHS around £1.5B (2011 costs),10,11 with total costs (including societal and
intangible costs) nearing £48.5B (2014 costs)12 per year. This compares with estimates of around
US$49.9B in the USA (2010 prices)13 and €48.4B in the European Union (2011 prices).14
At the time of developing this proposal in 2009/10, there was much uncertainty about the natural
history of COPD,5,15 how to approach early identification of patients16,17 and what interventions
were effective for early-stage disease. During the conduct of the programme, both the UK National
Screening Committee and the US Preventive Services Task Force (USPSTF) highlighted the lack of
randomised controlled trial (RCT) evidence that showed that screening for COPD is beneficial. We
therefore sought a variation to our contract to undertake additional work to that proposed in the
original funded application: to follow up trial participants to examine the impact of screening on clinical
outcomes. There was also little information on the impact that having COPD has on work performance
and occupation. Furthermore, most of the previous research to explore prognosis and natural history
of COPD were based on people with COPD recruited through secondary care and specialised settings,
rather than within primary care.18–20 The overall aim of this programme was therefore to recruit a
unique UK primary care COPD cohort to address some of these uncertainties and, as a platform for
future research, to test novel health service interventions.
Overview of research programme
The programme consisted of three inter-related work packages (WPs), each addressing several
research questions. Figure 1 provides an overview of the linked WPs in the programme, which are
briefly described below. Each WP is then described in more detail, outlining the rationale, the research
questions addressed and a summary of the findings and outputs linked to the original programme
objectives. A full list of publications arising from our programme is available in Appendix 1.
Work package 1: clinical trial to evaluate case-finding; TargetCOPD trial
The aim of this WP was to ascertain the most clinically effective and cost-effective approach to
identifying undiagnosed COPD. Initially, this was considered in terms of yield (WP1i), but with additional
follow-up (in a variation to the contract) in terms of clinical outcomes (WP1v and vi). A Markov model
was also developed to estimate the long-term cost-effectiveness of a systematic screening programme
for undiagnosed COPD. Finally, we explored the views of patients on the process and outcomes of
case-finding and the perspective of staff in primary care on the concept of case-finding and percieved
implications for their practice.
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WP3: COPD and occupational performance
i. Relationship between COPD and work 
    productivity  (employment, absenteeism 
    and presenteeism)
ii. Effect of disease progression on work productivity
iii. Feasibility of occupational intervention to 











i. Clinical effectiveness and cost-effectiveness of case finding on yield
ii. Health economic model of COPD screening
iii. Exploration of patient and primary care staff views
iv. Management of screen-detected COPD in primary care
v. Effectiveness of case-finding (hospitalisation and mortality)












(n = 6000) 
WP2: the Birmingham primary care COPD cohort
i. Cohort development (natural history)
ii. Test validity of existing prognostic model
iii. Development of BLISS prognostic model for primary care
iv. Exploration of barriers to and facilitators of home exercise 
                 Trial participants
• Case-found, n = 850
• Symptomatic normal, n = 1180
                                                                               Willing to take part and consent to
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• Prevalent, n = 1564
• Case-found, n = 330
• Symptomatic normal, n = 411
Individuals randomised by household 
                                                                    Occupation cohort
• Of working age, n = 600
• In employment, n = 350



























The objectives were to:
l ascertain the clinical effectiveness and cost-effectiveness of targeted case-finding (opportunistic or
active) compared with routine care
l develop a Markov model to compare the cost-effectiveness of systematic case-finding with
current practice
l explore the views of patients and primary care staff on COPD case-finding
l describe the clinical management of screen-detected COPD patients in primary care
l assess the long-term effectiveness of COPD case-finding on respiratory hospitalisations
and mortality
l compare outcomes among screen-detected COPD patients who were adequately managed by their
general practitioner (GP) with those among patients who were not.
Work package 2: Birmingham primary care chronic obstructive pulmonary disease cohort
The aim of this WP was to develop a cohort of more than 2000 people with COPD who would be
representative of those in a primary care setting, including more people with mild/moderate disease
than included in previous cohorts. Participants were recruited from COPD registers in general
practices as well as from participants in the TargetCOPD trial in WP1. This included those who
were identified through case-finding and those who took part in the case-finding trial and reported
respiratory symptoms but did not have COPD based on spirometry.
The participants were followed up every 6 months for around 3 years (2012–16) and their data were
linked to routine data on hospitalisation and mortality obtained from NHS Digital. We used these data
to externally validate an established prognostic model [the age, dyspnoea, airflow obstruction (ADO)
prognostic score] in predicting mortality. In addition, we developed a new prognostic model [the
Birmingham Lung Improvement StudieS (BLISS) index] to predict the risk of respiratory hospitalisation
in this primary care population.
A sample of 26 cohort participants were also invited to attend focus groups to explore barriers to and
facilitators of undertaking physical activity (PA), which is one of the most important components of
treatment for people with COPD.
The establishment of the cohort also provides an opportunity for testing novel interventions
in future.
The objectives were to:
l recruit a primary care cohort of 2000 new and existing COPD patients
l test the validity of existing COPD prognostic models in a primary care COPD population
l develop a prognostic model (BLISS index) to predict respiratory hospitalisations suitable for a
primary care population
l explore barriers to and facilitators of PA participation among people with COPD.
Work package 3: chronic obstructive pulmonary disease and occupational performance
The aims of this WP were to (1) examine the relationship between clinical characteristics and
severity of COPD and occupational outcomes, including employment, work absenteeism and
presenteeism (working while unwell); (2) examine whether or not disease progression over time
is associated with occupational outcomes; and (3) assess the feasibility and benefits of offering
formal occupational health (OH) assessment and subsequent recommendations aimed at improving
work-based indices. Participants in this WP were a subsample of the larger cohort recruited in WP2.
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The objectives were to:
l examine factors associated with occupational performance (employment, absenteeism and
presenteeism) among COPD patients of working age
l examine how disease progression (lung function decline, exacerbation) over time is associated with
occupational performance (employment, absenteeism and presenteeism) among COPD patients
in employment
l assess the feasibility of offering OH assessment with recommendations to people with COPD.
SYNOPSIS
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Work package 1: clinical trial to evaluate
case-finding – TargetCOPD trial
Objective (i): to ascertain the clinical effectiveness and cost-effectiveness
of targeted case-finding (opportunistic or active) compared with routine
primary care (work package 1i, published trial report)21
Parts of this section are based on Jordan et al.21 Reprinted from The Lancet Respiratory Medicine, Vol. 4,
Rachel E Jordan, Peymané Adab, Alice Sitch, Alexandra Enocson, Deirdre Blissett, Sue Jowett, et al.,
Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary
care (TargetCOPD): a cluster-randomised controlled trial, pp. 720–30, Copyright 2016, with permission
from Elsevier.
Rationale
Several reports from the UK government and health charities22,23 have highlighted the burden of
COPD, the extent of underdiagnosis and the variation in access to and participation in relevant services.
The Department of Health and Social Care published an outcomes strategy for people with COPD
in 2011 that recommended opportunist and the systematic case-finding to minimise late diagnosis.22
However, the most clinically effective and cost-effective approach for identifying undiagnosed
cases was not known. Although some published studies reported the yield from either active24–26
or opportunistic27–29 approaches to case-finding using spirometry, these were limited because of a
lack of comparison groups, the restricted number and range of participants, a lack of follow-up and
different target populations (e.g. specific age groups; all current smokers or people who have smoked;
whether or not symptoms were considered prior to spirometry). Furthermore, general population
screening using spirometry was not recommended16 because it would identify many people without
clinically important disease, for whom there is little evidence of effective interventions.30 We therefore
sought to evaluate different approaches to case-finding for undiagnosed COPD, focusing on yield and
cost-effectiveness (from a health-care perspective). To our knowledge, this was the first major trial to
compare different targeted recruitment approaches with case-finding with routine care.
What we did
We recruited 54 GP practices across the West Midlands (10 August 2012–22 June 2013) to take part in
the 12-month trial and randomised these clusters to case-finding or to continue with routine care. All
patients on the practice registers aged 40–79 years who had no existing diagnosis of COPD and had
ever smoked (based on GP electronic records) were eligible for and included in the trial. Using a computer-
generated randomisation sequence, we randomised practices (balanced on practice characteristics)
and in the intervention case-finding arm we randomised individual households of patients to receive
one of two approaches to case-finding: opportunistic (offered screening opportunistically when they
visited the practice for any reason) or active (additionally offered screening through a postal invitation).
Screening was carried out in two stages, with an initial questionnaire (see Appendix 2) followed by
an invitation to attend for diagnostic spirometry for those who reported relevant chronic respiratory
symptoms. Our study case definition of 1-year incident COPD was either (1) a new diagnosis of COPD
by the GP (based on new entry on practice COPD register) or (2) the presence of airflow obstruction on
screening [defined as forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 0.7 post
bronchodilator, in line with recommendations from the guidelines31 produced by the National Institute
for Health and Care Excellence (NICE)] in patients with chronic respiratory symptoms. Sample sizes
were based on estimates from our published model (see published paper21 for full details) and required
27,768 patients per group. Primary outcomes were analysed using appropriate regression analyses
adjusted for practice-level deprivation, ethnicity and age. The active versus opportunistic comparison
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required logistic regression with fixed effects and the targeted versus routine comparison required
multilevel models with random effects. We undertook a within-trial cost-effectiveness analysis to
calculate the cost per additional case detected of both strategies versus routine care, and we undertook
a detailed cost analysis of the screening processes using standard NHS32,33 and trial-specific costs34
(2013 prices), including set-up costs and training costs. Equipment and training costs were amortised
over 3–5 years using a discount rate of 3.5%. Sensitivity analyses considered patient costs, alternative
case-finding scenarios and models of care (GP, community or secondary care led).
What we found
A flow diagram of participants is available in the published paper.21 We found that very few new cases of
COPD were diagnosed in the routine care practices (n = 337; 0.8%). The odds of finding new cases were
seven times higher using the targeted approach than with routine care [n = 1278 (4%); adjusted odds ratio
(OR) 7.45, 95% confidence interval (CI) 4.80 to 11.55; p < 0.0001], and active case-finding (combining
opportunistic and active postal invitation to screening) was twice as effective as opportunistic-only
[n = 822 (5%) vs. n = 370 (2%); adjusted OR 2.34, 95% CI 2.06 to 2.66; p < 0.0001]. Active case-finding
may also be more cost-effective than the opportunistic approach (£333 vs. £376 per additional case
detected, respectively). The incremental cost-effectiveness ratio (ICER) for active case-finding was £573
per additional case detected compared with opportunistic case-finding. Sensitivity analyses made little
difference, although a secondary care-led service was more expensive.
Strengths and limitations
To our knowledge, this was the first RCT to compare yield of undiagnosed COPD from a comparison of
different screening approaches with routine practice and to estimate their cost-effectiveness. However,
the efficiency of screening could have been improved by using different screening tests, or pre-screening
algorithms applied to electronic health records (EHRs) to target screening invitations to those at highest
risk. Even with the most intensive screening approach, only 38% of those invited for screening responded,
and not all those who responded and had symptoms attended for diagnostic spirometry. Further research
should focus on how to maximise screening coverage and uptake and improve the efficiency of the
screening process.
Objective (ii): to develop a model (using Markov decision analysis) to
compare the cost-effectiveness of a systematic case-finding programme
with current practice (work package 1ii, published)35
Rationale
The TargetCOPD trial confirmed that active approaches to screening result in a higher proportion of
undiagnosed COPD patients being identified compared with routine care. People with screen-detected
COPD are expected to benefit from treatment resulting in improved quality of life, increased survival
and reduction in hospital admissions. To provide data for policy-makers to consider the longer term
benefits of screening for COPD in relation to investment in other health services, a cost-utility model
is needed. Published economic evaluations in COPD have primarily considered interventions for the
disease rather than for those who are screen detected,36 and others have concentrated on the costs of
COPD in burden of illness studies.37 No trial-based economic evaluation had considered case-finding.
NICE guidelines38 included a simple decision tree-based modelling to determine the cost-effectiveness
of opportunistic case-finding among people aged > 35 years who have smoked and have a chronic
cough. However, the model was simplistic and included many assumptions for which evidence was
limited. We developed a model-based economic evaluation of the long-term costs and benefits of
screening for undiagnosed COPD.
What we did
We used costs (using 2015 prices39) and outcome data from the TargetCOPD trial, in combination
with the best available published data, and additional information from our linked Birmingham COPD
cohort study (WP2) to develop a Markov decision-analytic model to address this objective. The model
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compared the cost-effectiveness of a 3-yearly systematic case-finding programme aimed at people
aged > 50 years who have smoked with current practice because the yield of new cases was very small
in younger age groups. The model had a time cycle of 3 months, which was short enough to capture
important COPD-related events, and a time horizon of 50 years, assuming a maximum age of 100 years.
Patient-level data on case-finding pathways were obtained from our TargetCOPD RCT. The model
outcome was cost per quality-adjusted life-year (QALY) gained, from a health service perspective.
Discounting was applied to costs and outcomes at 3.5%. Multiple one-way sensitivity analyses assessed
what impact modification of key parameters had on the results. We considered varying the starting age,
screening interval and time horizon as well as the screening processes (questionnaire response,
spirometry attendance rate), treatment initiation rates and effectiveness of treatments.
What we found
We estimated the ICER of systematic case-finding compared with routine care to be £16,596 per
additional QALY gained. Using the commonly used willingness-to-pay threshold in the UK (£20,000
per QALY), we estimated there was 78% probability of cost-effectiveness. The estimate was robust to
sensitivity analyses, with the main cost-driver being uptake of screening. The most cost-effective age
to begin screening was around 60 years. Better ascertainment of treatment effectiveness will help
improve precision but, using the best current estimates from the literature,40,41 screening is likely to be
cost-effective provided that at least 12% respond to a screening questionnaire, > 26% attend spirometry
and > 8% of screen-detected patients are adequately treated and managed.
Strengths and limitations
To our knowledge, this is the first economic model to evaluate the long-term cost-effectiveness of a
COPD case-finding strategy, using contemporaneous data sources to inform estimates and using multiple
sensitivity analyses to test the robustness of the model. However, the validity of some of the assumptions
underlying the model is unknown. In particular, there is uncertainty around the effect of treatment on
progression and the natural history of COPD. Future research should refine the model based on data
from studies that provide more accurate estimates of effectiveness and consider additional costs, such
as those to the health service, of pathways to deal with a larger number of identified cases.
Objective (iii): to explore the views of (a) patients invited to take part in
case-finding, in terms of the process and outcomes (work package 1iii,
published),42 and (b) primary care staff, in relation to case-finding
(work package 1iii, published)43
Rationale
Although there has been much research examining the yield from different case-finding activities, few
previous studies have examined other aspects related to the development of a screening programme.
One important aspect is the acceptability of screening and understanding the perspective of both
patients and those who provide screening. We undertook two studies: one to explore the views of
patients who had been invited for screening as part of the TargetCOPD trial, about the screening
process and outcomes, and another to understand the process from the perspective of primary care
staff who would manage those who are case-found.
What we did
For the patient perspective, we invited for interview people who had been invited for screening in
either the active or opportunistic arm as part of the TargetCOPD trial (i.e. adults aged ≥ 40 years
with a smoking history who had been considered eligible for the trial by their GP). We invited four
groups of patients: those who (1) were invited and consented to take part in screening, (2) were
invited and declined, (3) attended screening but did not have COPD and (4) attended and had
abnormal lung function suggesting COPD. We sought their views on the screening process and their
reflections on the outcomes of screening.
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For the primary care staff perspective, we invited 20 staff, including GPs, nurses and managers in
practices that had taken part in the TargetCOPD trial. Participants were invited to share their views on
COPD case-finding, including their perceptions of the benefits, harms, and barriers to and facilitators
of implementing a screening programme in primary care.
For both studies, interviews were transcribed and analysed using the framework approach.
What we found
Forty-three patients and 20 health-care staff were interviewed. Patients generally considered screening
to be a good thing, and the presence of symptoms on prompting facilitated their attendance. The
importance of ensuring that the screening process is convenient was highlighted, and patients worried
that GPs did not have the time to follow up after screening.
Barriers to attending screening included psychological and practical factors. The former related to denial
and failure to recognise symptoms, fear of the ‘test’ and perceiving lung disease as less important within
the hierarchy of their health problems. Practical barriers included lack of time, inability to access GP
appointments and having caring and other responsibilities that were considered more important.
Among primary care staff, although they also generally supported screening for undiagnosed COPD,
they also commented on concerns around potential negative consequences, including an increase in
workload for GPs and overdiagnosis in patients. Some commented that, currently, diagnosed patients
were not being adequately treated. Perceived barriers to implementing screening included lack of
resources and limited access to diagnostic services. However, potential solutions, including better
support from secondary care, an increase in specialist COPD nurses and better community respiratory
service provision, were also discussed. Poor knowledge of COPD in terms of recognising symptoms and
how to manage those with the disease was also highlighted as a problem that needs to be addressed.
For a screening programme to be implemented and have high uptake, it is important to raise patient
awareness of COPD risk factors and symptoms and provide training and additional resources for
primary care. In particular, it is important to ensure that management pathways for diagnosed COPD
patients are optimised before further cases are identified.
Strengths and limitations
To our knowledge, this was the first study to explore perceptions of patients and health-care providers
on different stages of case-finding. However, we did not explore experiences of the approach to
recruitment for screening (questionnaire at GP surgery or by post) and no participant commented on
this. In addition, we did not invite and have not captured the views of people who reported no chronic
respiratory symptoms as part of screening. Furthermore, inviting patients in the context of research
may not reflect views on screening in practice. For health-care staff, those who participated are likely
to be more engaged in case-finding and their views may represent those who are more proactive in
management of case-found COPD.
Objective (iv): to describe the clinical management of screen-detected
chronic obstructive pulmonary disease patients in primary care and
compare management in those who were versus those who were
not on the practice chronic obstructive pulmonary disease registers
(work package 1iv, manuscript submitted)
Rationale
From a public health perspective, screening is more than a screening test. To have an impact on clinical
outcomes, a number of criteria need to be fulfilled and, in the UK, the National Screening Committee
considers these carefully before recommending commencement of a population screening programme.
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The criteria relate to the condition, the screening test, the treatments available for those who are
screen detected and the characteristics of the programme and its implementation. In relation to the
programme implementation, it is important to ensure that resources are available and pathways
are in place to manage screen-detected individuals. In the UK, NICE has set out a pathway for the
diagnosis and management of people with COPD.31 As part of the TargetCOPD trial, patients with
chronic respiratory symptoms who attended spirometry screening had their results fed back to their
GP, with a note for them to follow NICE guidelines for further management. However, there are
few studies that have examined how patients diagnosed with COPD are subsequently managed
and whether or not primary care staff follow recommended pathways for managing these patients.
We therefore obtained data from GP EHRs and self-reported data from case-found patients (those
with airflow obstruction on spirometry who fulfil the NICE recommended criteria for diagnosing
COPD) to describe the clinical management of case-found COPD patients (identified through the
TargetCOPD trial) and compare this with that of patients newly diagnosed with COPD through routine
care. In addition, we compared characteristics and management for those who were or were not
entered on to the practice COPD register.
What we did
We identified patients who had been newly diagnosed with COPD (case-finding, n = 857; routinely
diagnosed, n = 764) during the period August 2012 to June 2014 in the 54 GP practices that took part
in the TargetCOPD trial. Data on demographic and clinical characteristics, as well as a range of clinical
assessments and interventions recommended by NICE for people with COPD, were extracted from
EHRs for a subset of patients covering the period April 2011 to September 2017. In addition, patients
who had been identified through case-finding were invited to complete a health questionnaire around
5 years after their first diagnosis, in March 2018, with a reminder 2 months later.
For all patients, we determined whether or not they had been added to the practice COPD register
used in reporting for the Quality and Outcomes Framework (QOF) by the end of the TargetCOPD trial
period. The number of COPD-related clinical assessments and interventions were summed to form a
clinical management score. Multilevel logistic regression was used to assess for associations between
participant characteristics and the likelihood of being added to a disease register, comparing those who
were identified through case-finding with those routinely diagnosed. Multilevel linear regression was
used to assess associations between participant characteristics, COPD disease registration and the
clinical management score.
What we found
Figure 2 shows a summary of participants included in these analyses. The primary analysis showed that
just over one-fifth (182/857; 21.2%) of case-found patients, but almost all of the routinely diagnosed
patients (708/764; 92.7%), had been added to the QOF COPD register within 12 months of assessment
[median time from trial spirometry assessment to COPD registration 152 days, interquartile range (IQR)
72–258]. Factors associated with a higher likelihood of COPD registration among case-found patients
were current and former smoking (adjusted OR 8.68, 95% CI 2.53 to 29.82, vs. OR 6.32, 95% CI 1.88 to
21.29, respectively) and lower percentage of predicted FEV1 (OR 0.96, 95% CI 0.95 to 0.98).
Electronic health record data were available for 532 out of 1629 patients (identified through case-
finding, n = 344; identified through usual care, n = 188) (Table 1). The characteristics of participants
with and without EHR data were broadly similar. Factors associated with a higher clinical management
score were being on the COPD register (adjusted β 5.06, 95% CI 4.36 to 5.75, which means that the
score was on average 5 units higher for those on the COPD register than for those not on the register)
and a higher number of comorbidities (adjusted β 0.38, 95% CI 0.11 to 0.65, which means that the
score increased by 0.38 units for each additional comorbidity). Although of only borderline statistical
significance, there was also a negative association with being case-found rather than routinely
diagnosed (adjusted β –0.69, 95% CI –1.44 to 0.07).
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FIGURE 2 Flow of participants contributing to analyses for this study. a, Included in current study.
TABLE 1 Clinical management during the 2-year follow-up of participants with EHR data who were case-found vs. those
clinically diagnosed through usual care
Diagnosis
Case-finding (N= 344) Usual care (N= 188)
na % na %
Clinical assessment
MRC dyspnoea score recorded 98 28.5 171 91.0
CAT score recorded 36 10.5 94 50.0
Spirometry undertaken 48 14.0 79 42.0
COPD severity recorded 33 9.6 96 51.1
BMI recorded 244 70.9 168 89.4
Oxygen saturations recorded 41 11.9 55 29.3
Chest X-ray undertaken 13 3.8 9 4.8
Depression screen undertaken 54 15.7 55 29.3
Clinical intervention
Listed on COPD register 78 22.7 175 93.1
Care plan recorded 38 11.0 97 51.6
Annual review undertaken 91 26.5 170 90.4
Smoking cessation counselling provided 157 45.6 139 73.9
Nicotine replacement therapy 27 7.8 17 9.0
Influenza vaccination provided 240 69.8 138 73.4
Pneumococcal vaccine provided 19 5.6 23 12.2
Pulmonary rehabilitation provided 17 4.9 42 22.3
Inhaler technique assessed 56 16.3 116 61.7
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Self-reported questionnaire data were available for 375 out of 857 case-found patients. Only one-fifth
of these patients were on the COPD register and, overall, one-third were aware of their diagnosis
through their GP (88.5% of those on the COPD register vs. 17.5% of those not on the register).
Around 45% had attended a COPD annual review, with the proportion being higher for those on the
COPD register (83.3% vs. 34.7%). Factors associated with a higher clinical management score in this
group were having a larger number of comorbidities (adjusted β 0.38,95% CI 0.10 to 0.65), higher
COPD Assessment Test (CAT) score (adjusted β 0.05, 95% CI 0.01 to 0.08) and lower percentage of
predicted FEV1 (adjusted β –0.03, 95% CI –0.04 to –0.01). Being on the COPD register was also
significantly associated with a higher management score (adjusted β 3.48, 95% CI 2.81 to 4.15).
A proportionately high number of case-found patients with COPD were not added to practice COPD
registers and these patients were less likely to receive recommended effective treatments for their
condition. Overall, even those who were on the COPD register did not receive all recommended
interventions, including smoking cessation advice or referral to pulmonary rehabilitation.
Strengths and limitations
This is one of the largest studies to evaluate the clinical management of screen-detected COPD
patients in primary care. The lack of availability of EHR data on all trial participants was a limitation,
and the validity of the EHR data is dependent on the clinical coding practices used. Nevertheless,
the missing data are likely to be random, based on similarity of characteristics between those with
and without data. Furthermore, the self-reported data from those who responded to questionnaires
broadly verified the findings from health records.
TABLE 1 Clinical management during the 2-year follow-up of participants with EHR data who were case-found vs. those
clinically diagnosed through usual care (continued )
Diagnosis
Case-finding (N= 344) Usual care (N= 188)
na % na %
Inhaler prescribed
Salbutamol 128 37.2 152 80.9
Ipratropium 5 1.5 10 5.3
Salmeterol 3 0.9 10 5.3
Fluticasone 3 0.9 1 0.5
Budesonide 0 0.0 0 0.0
Beclometasone 20 5.8 13 6.9
Fluticasone/salmeterol 33 9.7 70 37.2
Budesonide/formoterol 12 3.5 23 12.2
Any of the above inhalers 134 39.0 163 86.7
Antibiotic rescue pack 10 2.9 43 22.9
Prednisolone 51 14.8 96 51.1
Clinical management score
< 5 225 65.4 17 9.0
5 to 9 83 24.1 73 38.8
≥ 10 33 9.6 98 52.1
Median (IQR) 3 2–5 10 7–12
BMI, body mass index; CAT, COPD Assessment Test; MRC, Medical Research Council.
a Number of participants who received the clinical assessment or intervention.
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Objective (v): to assess the long-term effectiveness of case-finding for chronic
obstructive pulmonary disease on respiratory hospitalisations and mortality
(work package 1v, manuscript in preparation) and objective (vi): to compare
outcomes (including health-related quality of life) among screen-detected
chronic obstructive pulmonary disease patients in primary care who were
managed adequately by their general practitioner (based on the practice
chronic obstructive pulmonary disease registers) with those who were not
Rationale
Since starting our programme of work, the UK National Screening Committee undertook a review to
consider screening for COPD44,45 and the USPSTF updated their review.46 Both recommended against
screening for the time being, citing the need to establish evidence on clinical effectiveness of early
identification before recommending systematic programmes for screening. The benefits of case-finding
in improving health-related quality of life (HRQoL) and QALY gains has also not been previously studied.
Through our original trial, the infrastructure was in place to assess whether or not screening and early
detection of COPD benefited patients in the longer term. We therefore sought a variation to the
contract to extend follow-up and to link data on all patients who were part of the original trial with
routinely available data. We obtained data on all eligible participants from NHS Digital on hospitalisations
[through Hospital Episode Statistics (HES) data] and mortality, from the start of the trial until the last date
available. We also sought approval from the National Research Ethics Committee and legal approval
from the Confidentiality Advisory Group to obtain relevant patient identifiable data from GP practice
records through an opt-out process and hold these temporarily to allow data linkage with the data
obtained from NHS Digital. We were then able to compare outcomes among those who were in
practices where active screening took place with those in the routine care arm practices (WP1v).
Additionally, to improve the input into the health economic model developed previously, we sought to
obtain additional data on quality of life among screen-detected COPD patients some years after diagnosis
and to compare outcomes among those who were managed in accordance with NICE guidelines with
outcomes among those who were not.
What we did
Data on mortality and hospitalisations (all-cause and respiratory) were obtained for all eligible patients
(who were alive at the start of the intervention, n = 74,693) from 54 participating practices in the
TargetCOPD trial. Patient demographic data and information on whether or not the patient was
on the practice QOF COPD register within 12 months of the trial were obtained from GP records.
We also administered a questionnaire in 2017/18 to all case-found patients identified through the
TargetCOPD trial to invite them to respond to questions on quality of life as well as their health
and treatments received for COPD. Cox proportional hazard models, using random effects to account
for clusters and adjusted for potential confounding factors, were used to model the time to event
outcomes (death, first all-cause hospital admission and first respiratory hospital admission) in the
intervention (active or targeted) and routine care arms. The time to event was censored at the death
(for admission outcomes) or data extraction (30 September 2017 for hospital admissions and 13 October
2017 for deaths) if no event occurred. We also compared outcomes for the two intervention arms
(active and opportunistic). Finally, for screen-detected cases, we compared mortality and hospitalisation
as well as HRQoL measures [EuroQol-5 Dimensions (EQ-5D) and CAT scores] among those who were
or were not added to the practice QOF register. Based on data from objective v, we used addition to the
practice COPD register as a proxy measure for being better managed and treated for COPD. Analyses
were adjusted for baseline values as well as for a range of potential confounders, including age, sex,
ethnicity and baseline values for lung function, comorbidities and smoking status.
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What we found
Among the 32,743 participants in the case-finding arms, 1557 had a respiratory hospitalisation compared
with 1899 among the 41,950 participants in the routine arm over a mean follow-up period of 4.3 years
[adjusted hazard ratio (HR) 1.04, 95% CI 0.73 to 1.47]. The corresponding HR for all-cause hospitalisation
and mortality were 1.06 (95% CI 0.66 to 1.71) and 1.15 (95% CI 0.82 to 1.61), respectively, suggesting
that, overall, there was no significant difference in risk of first hospitalisation and mortality between
those who were in the screening arm compared with those in the routine care arm of the trial.
Within the two intervention groups in the case-finding arm there was no statistically significant difference
between groups in terms of overall hospitalisations and mortality (adjusted HR 1.01, 95% CI 0.98 to 1.04,
and adjusted HR 1.08, 95% CI 0.96 to 1.20, respectively). The adjusted HR for respiratory hospitalisation
in the active group compared with the opportunistic group was 1.14 (95% CI 1.02 to 1.27), indicating an
increased hazard of respiratory admissions in the former group (where yield from screening was higher).
Comparison of outcomes for screen-detected patients who were on the QOF COPD register with those
who were not also showed no statistically significant difference in relation to all-cause hospitalisation
(adjusted HR 0.86, 95% CI 0.66 to 1.11), respiratory hospitalisation (adjusted HR 0.95, 95% CI 0.52 to
1.73) and mortality (adjusted HR 1.06, 95% CI 0.53 to 2.12).
Thus, despite screening resulting in a higher yield of undiagnosed cases of COPD, there was no
difference between those who were in practices with or without screening in terms of clinical outcomes
at 4 years. The poor clinical management of COPD generally, and very low addition of case-found
patients (particularly those with less severe disease) to the practice COPD register, may be an
explanation for the findings. Given these results, we did not undertake a health economic analysis to
examine cost per hospital admission avoided or cost per life-year saved.
In the adjusted analyses examining HRQoL, there was no statistically significant difference in EQ-5D
scores between the two groups (adjusted mean difference –0.006, 95% CI –0.048 to 0.036). The
adjusted mean CAT score was statistically significantly and clinically higher in those who were on the
COPD register than in those who were not (mean difference 2.317, 95% CI 0.481 to 4.153), indicating
a greater impact of COPD on their life and poorer quality of life. This difference is likely to reflect the
more severe disease and characteristics of those who are added to the COPD register compared with
those who are not, rather than being a result of how they were managed.
Strengths and limitations
To our knowledge, this is the first trial to report clinical outcomes from a large trial of screening for
undiagnosed COPD. The trial was not powered to detect clinical outcomes because that was not the
primary aim, but, nevertheless, it has provided reasonable effect estimates. The poor clinical management
of people with screen-detected COPD limits the ability of detecting any potential benefits and thus the
interpretation of findings. The low proportion of screen-detected patients being entered on the COPD
register may explain the observed lack of effectiveness of screening.
Additional outputs and published analyses related to work package 1
The main TargetCOPD trial paper was disseminated more widely at respiratory conferences
internationally and won the following awards:
l Royal College of General Practitioners (RCGP) award for ‘best paper of the year 2016’ in
Category 2 (CVD, Renal, Respiratory, Oral, ENT & Ophthalmology).
l European Respiratory Society (ERS) best abstract in primary care 2015.
l American Thoracic Society (ATS) best abstract Clinical Problems Assembly 2015.
l Society for Academic Primary Care nomination for best abstract 2015.
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Additional related papers include the following.
Jordan et al.47
This was the protocol for the TargetCOPD trial, outlining the rationale, methods and analysis plan.
Miller et al.48
In this analysis we used data from the TargetCOPD trial and compared how the application of
two different definitions of airflow obstruction would impact on the clinical characteristics of the
population who would be labelled as having COPD. The definition used in the trial was based on the
ratio of FEV1/FVC < 0.7 [the fixed ratio (FR)], which is recommended by NICE. The second definition
was based on using the lower limit of normal (LLN) that is increasingly being recommended. We found
that, among 2607 people who attended for spirometry, around one-third had airflow obstruction using
the FR definition compared with 20% using the LLN definition. There was overlap between the two
groups. However, those identified by the FR and not the LLN definition were older, had better lung
function and fewer respiratory symptoms, but had a higher rate of heart disease. Overall, we
demonstrated that using the FR rather than LLN identifies a greater proportion of individuals with
cardiac, rather than respiratory, clinical characteristics.
Haroon et al.49
This analysis used data from the TargetCOPD trial to develop a validated algorithm and risk score to
target case-finding on those at highest risk of undiagnosed COPD and thus improve the efficiency of
any future case-finding process. Although other COPD risk scores have been developed, this was the
first that was based on identifying case-found COPD (rather than incident clinical COPD diagnosed
through routine care) and is therefore more useful in the context of case-finding in primary care.
Haroon et al.50
In this analysis we used a case–control study design to match incident COPD cases from 340 GP
practice registers (using the UK Clinical Practice Research Datalink) to two controls (based on age,
sex and practice). Predictive risk factors for COPD were identified from practice records and used to
develop a clinical risk score. The risk score was validated using a sample from a further 20 practices.
The model, including smoking status, history of asthma and lower respiratory tract infections, and
prescription of salbutamol in the previous 3 years, resulted in reasonable prediction (c-statistic 0.85,
95% CI 0.83 to 0.86).
Haroon et al.51
This systematic review (based on studies from 1997 to 2013) summarised the uptake and yield from
different approaches to screening for undiagnosed COPD in primary care. Data from three RCTs, one
non-randomised trial and 35 uncontrolled studies showed that all approaches result in identification of
new undiagnosed cases. The review suggested that targeting higher-risk individuals (e.g. smokers) and
using questionnaires or handheld flow meters prior to diagnostic screening was likely to increase yield.
However, it also highlighted the need for well-conducted RCTs.
Haroon et al.52
This review compared the diagnostic accuracy of different COPD screening tests in primary care.
A total of 10 studies were identified from 1997 to 2013 and included use of screening questionnaires
[mainly the COPD Diagnostic Questionnaire (CDQ)], handheld flow meters [e.g. the copd-6 (Vitalograph
Ltd, Buckingham, UK)] or a combination. Handheld flow meters demonstrated higher test accuracy
than questionnaires but the review highlighted the need for high-quality evaluation of comparative
screening strategies.
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Work package 2: the Birmingham primary
care chronic obstructive pulmonary
disease cohort
Objective (i): to recruit a cohort of 2000 new and existing chronic
obstructive pulmonary disease patients from general practices in the
West Midlands (work package 2, linked to work package 1, published)53
Rationale
The natural history of COPD is still not understood, and several expert reviews have highlighted a
need to further investigate both old and new longitudinal data.5,15 Prior to this programme, a number
of relevant COPD disease cohorts had been established,54–56 but these included patients with more
advanced disease from secondary care settings, with short duration of follow-up, and were mainly
of small size. Other large population cohorts have also been used to address questions relevant to
COPD.57–60 However, because these were not specifically set up to address COPD, not all relevant
measures were undertaken and the quality of lung function was not always prioritised. There were no
UK primary care COPD cohorts with patients representing the range of disease severity, particularly
including people with mild/moderate disease, or a diverse socioeconomic mix. Furthermore, existing
cohort studies included neither people with COPD who were identified through case-finding nor
patients reporting respiratory symptoms but who had normal lung function [former Global Initiative
for Chronic Obstructive Lung Disease (GOLD) stage 0].61 The evidence on progression to COPD in the
latter group is limited and contradictory,62–64 and methods for assessing symptoms are inconsistent.62,65
The clinical relevance and natural history for this patient group and screen-detected cases are unclear.
What we did
We recruited 2305 patients aged ≥ 40 years from 71 practices across the West Midlands (Figure 3),
comprising 1564 patients with previously diagnosed COPD, 330 previously undiagnosed patients
with respiratory symptoms and airflow obstruction confirmed by spirometry (case-found COPD)
and 411 symptomatic patients with normal lung function confirmed by spirometry.53
Baseline assessments were undertaken by trained researchers using standardised protocols between
2012 and 2014 (Figure 4). Assessments included high-quality pre- and post-bronchodilator spirometry
using an ndd EasyOne® spirometer (ndd Medizintechnik AG, Zurich, Switzerland). Other measurements
included height and weight, body fat percentage estimation using the Tanita BC-420SMA Body Composition
Analyser (Tanita Europe BV, Amsterdam, the Netherlands), assessment of grip strength using a Saehan
Hydraulic Hand Dynamometer (Saehan Corp., Masan, Republic of Korea) and assessment of exercise
capacity using the sit-to-stand test. In addition, trained researchers used face-to-face interviews to obtain
occupational history. Information on skill content of occupations was used to assign a four-digit standard
occupational classification (SOC2010)66 code for current or main occupation using the CASCOT (computer
assisted structured coding tool) software (online version, Office for National Statistics, Newport, UK).
Participants were also asked to complete questionnaires that sought data on demographic characteristics,
lifestyle (smoking history and exercise habits), symptoms, exacerbation history, general health, diagnosed
medical conditions, health-care usage and the home environment (see Appendix 3). HRQoL was assessed
using disease-specific (CAT)67 and generic (EQ5D)68 instruments, and the Patient Health Questionnaire-9
(PHQ-9)69 instrument was used to screen for depression.Work productivity was assessed through
questions on work absence and presenteeism using the Stanford Presenteeism Scale (SPS-6)70 and the
Work Productivity and Activity Impairment questionnaire (WPAI).71
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At 6-monthly intervals, patients were sent follow-up questionnaires by post. All follow-up questionnaires
included items on employment, general health, lung health, exacerbations, new diagnoses, attendance at
pulmonary rehabilitation, health-care utilisation, smoking history, medications, depression and HRQoL.
Some questionnaires included additional items, which are summarised in Table 2.
Patients were invited for a final assessment visit around 3 years after baseline (2015–16). In addition
to post-bronchodilator spirometry, other baseline assessment measures and questionnaires were
repeated. Cohort participants’ routine data on comorbidities and medications were extracted from GP
records. Linked data on hospital episodes and mortality were also obtained from NHS Digital for the









































































































































































FIGURE 4 Cumulative number of cohort participants recruited and having baseline assessments by month.
TABLE 2 Cohort questionnaire items and response rate at different follow-up points
Questionnaire Special items in questionnaire
Response
rate (%)
6 months Self-management, exercise, COPD knowledge, major events 73.0
12 months Major events 67.6
18 months Handwashing, diet 69.2
24 months Self-management, handwashing, exercise, self-efficacy 66.1
30 months Pain symptoms, fatigue 62.8
Follow-up assessment Exercise, smoking cessation, e-cigarette use, major events, sleep, vitamin use 88.3
Supplementary Anxiety, illness perception, self-perception 78.8
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Establishment of this cohort allowed important questions of relevance to patient benefit to be
addressed (WP2i).
What we found
Follow-up data were available for 2250 patients (97.6%), and almost two-thirds (1469, 63.7%)
returned for face-to-face follow-up assessment. Six-monthly questionnaires were completed by around
two-thirds of patients (62.8–73.0%; see Table 2). In the initial 2 years of follow-up, 267 (12%) patients
had at least one respiratory-related hospital admission, based on HES data. Over the entire period of
follow-up (minimum 1.8 years, maximum 3.8 years), 382 patients (17%) had at least one respiratory
hospital admission and 170 (7%) had died at the time data were obtained from NHS Digital.
Strengths and limitations
We established one of the largest primary care COPD cohorts, which is novel in that it includes
case-found patients. A limitation was that fewer than one-third of case-found patients agreed to join
the cohort. Our recruitment strategy resulted in an over-representation of patients with less severe
disease because patients had to be ambulatory. Despite attempts to include patients from diverse
ethnic backgrounds, the majority were white.
Objective (ii): to test the validity of existing chronic obstructive
pulmonary disease prognostic models in a primary care chronic obstructive
pulmonary disease population (work package 2, published);72 and
objective (iii): to develop a prognostic model (BLISS index) to predict
respiratory hospitalisations suitable for a primary care population
(work package 2, drafted, see Appendix 4)
Rationale
A better understanding of factors predicting prognosis and the development of a prognostic model can
facilitate doctor–patient consultations and inform management decisions and health service planning.
For COPD, a simple measure of lung function, FEV1, has historically been used to grade severity.
However, there is increasing recognition that this measure is not a good predictor of clinical outcomes.
Alternative measures of lung function may improve diagnostic73 and prognostic ability.74,75
A number of studies have also described a range of factors other than lung function that are associated
with COPD progression, deriving prognostic indices. The first [BODE (body mass index, airflow
obstruction, dyspnoea, and exercise) index] was developed to predict mortality risk in those with COPD.56
However, the method of development was not clear, its validity has not always been confirmed and not all
measures are practical in non-specialist settings.76 Since then, several other prognostic models have been
developed and, since we started the programme, a number of systematic reviews have been undertaken
to summarise these.77–79 The reviews show that existing prognostic models are heterogeneous in terms of
the number and type of predictors, the prognostic outcome, time horizon and statistical approach. Most
focus on predicting mortality risk,56,76,80–82 although others were developed to predict additional outcomes
such as exacerbations,83,84 COPD-related hospitalisation,85 respiratory hospital attendance/admission86 and
exacerbation or hospitalisation.87,88 Only three indices84,87,88 were derived from primary care populations,
despite this being where most COPD patients are managed, and most included patients with more
severe established disease. No models were developed in populations that included case-found patients.
Few studies were validated or used recommended statistical approaches for deriving the model.
The most recent review showed that the ADO index was most discriminatory in predicting mortality.78
For a prognostic model to be used by clinicians, it needs to be simple and capture the required patient
data with minimum resource;89 the ADO index fulfils these criteria. We therefore undertook validation
of the ADO index for mortality within our cohort (WP2, objective ii).
WORK PACKAGE 2
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However, in relation to predicting respiratory hospitalisation, which is an important outcome to consider,
current models have moderate discriminative ability. This suggests that other relevant predictors are
missing from these prognostic models. We therefore derived a new COPD prognostic model, the BLISS
index, for use in a primary care population (with 2-year respiratory hospitalisation as primary outcome
and all-cause hospitalisation, exacerbations, primary care consultations and mortality as secondary
outcomes), using recommended statistical techniques (WP2, objective iii, draft paper; see Appendix 4).
What we did (objective ii)
We validated the ADO index using data from 1701 patients from the Birmingham COPD cohort study
(case-found or on the practice COPD register) who had complete data for the variables required for
this study. We externally validated the ADO index for predicting 3-year mortality, with 1- and 2-year
mortality as secondary end points. Discrimination was calculated using area under the curve (AUC),
also known as the c-statistic, and calibration was assessed using a calibration plot with locally weighted
scatterplot smoothing (LOWESS) and measures such as the calibration slope. In sensitivity analyses, we
included only patients with existing COPD and those with complete data.
What we found (objective ii)
The ADO index was discriminatory for predicting 3-year mortality (c-statistic 0.74, 95% CI 0.69 to 0.79),
with similar discriminatory ability for 1- and 2-year mortality (c-statistic 0.73, 95% CI 0.66 to 0.80, and
c-statistic 0.72, 95% CI 0.67 to 0.76, respectively). The ADO index overpredicted mortality at each time
point, which was more pronounced at 1- and 2-year mortality time points (calibration slopes 0.95, 0.79
and 0.79 for 3-, 2- and 1-year mortality, respectively) and in those with higher baseline ADO scores.
Thus, although the ADO index shows promising discrimination in a primary care population, the model
may need to be recalibrated if the ADO index is used to provide well-calibrated risk predictions for
1- or 2-year mortality. Discrimination and calibration were similar in sensitivity analyses.
What we did (objective iii)
To develop and internally validate a new prognostic model in primary care to predict respiratory
hospital admissions within 2 years, we linked self-reported and clinical data for all patients with COPD
from the Birmingham COPD cohort (331 case-found and 1558 previously diagnosed) with routine
HES obtained through NHS Digital. The primary outcome for the prognostic model was the occurrence
of a respiratory-related hospital admission (using primary diagnostic codes) from entry to the cohort
study up to 2 years (May 2012 to June 2014). Secondary analysis considered outcomes during the full
period until the NHS Digital data were obtained (1 April 2016). The maximum follow-up time was
around 4 years.
A list of 23 candidate variables was drawn up based on those included in other models for COPD,
along with other variables identified by a consensus panel comprising study investigators, clinicians
and patients. The degree of airflow obstruction was deemed clinically important but, owing to the
documented statistical problems with the commonly used FEV1% predicted (FEV1 as a percentage of
what would be predicted as normal),75 the best variable to be included in the model was not clear.
We therefore tested three variables as candidate predictors in the model [FEV1% predicted, forced
expiratory volume in 1 second quotient (FEV1Q), and FEV1/height2]. With 267 events for the primary
outcome, up to 26 candidate variables could be used, based on the rule of thumb of 10 events per
candidate variable.90
The model was developed using backward elimination with p< 0.157 for retention. Fractional polynomials
were considered and multiple imputation using chained equations was used for missing data. Discrimination
was assessed using the c-statistic and calibration was also assessed. Bootstrapping was used for internal
validation and the optimum-adjusted performance statistics were presented. A sensitivity analysis was
conducted using only those with previously diagnosed COPD.
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What we found (objective iii)
Over a median follow-up of 2.9 years (range 1.8 to 3.8 years), 382 participants (16%) had a respiratory
admission and 267 (12%) had a respiratory admission in the primary 2-year period. Participants with
hospitalisations were more likely to be older (70.3 vs. 67.0 years; p < 0.001), be male (66% vs. 59%;
p = 0.017), be more deprived [median Index of Multiple Deprivation (IMD) score of 30.3 vs. 24.4;
p = 0.0025], have a lower body mass index (BMI) (mean 28.2 vs. 28.8 kg/m2; p = 0.108), have more
severe airflow obstruction (mean FEV1% predicted 56.5% vs. 75.2%), have worse dyspnoea [Medical
Research Council (MRC) dyspnoea grade 3 57.5% vs. 51%; p < 0.001] and have worse quality-of-life
scores (median CAT score 24 vs. 17; p < 0.001). They were more likely to report previous exacerbations
based on the use of antibiotics or steroids (60% vs. 43%; p< 0.001) and to report previous hospitalisations
in the previous 12 months (18.4% vs. 2.6%; p < 0.001). Participants with hospitalisations were also
more likely to report a higher rate of vapours, gases, dusts or fumes (VGDF) (71% vs. 62%; p = 0.004),
to report exposure to smoking (31% vs. 27% current smokers; p = 0.019) and to have diabetes (24% vs.
15%; p = 0.001) and cardiovascular disease (20% vs. 15% with coronary heart disease; p = 0.049).
Using a pragmatic approach to model development, and including only variables that are widely available
or feasible to obtain in primary care, six variables were retained in the final developed model: age, CAT
score, respiratory admissions in the previous 12 months, BMI, diabetes and FEV1% predicted. After
adjustment for optimism, the primary model performed well in discriminating between those who will and
those who will not have 2-year respiratory admissions (c-statistic 0.75, 95% CI 0.72 to 0.79). Four further
variables were included in the secondary analysis but had similar score performance. Sensitivity analysis
with prevalent COPD cases resulted in an identical apparent c-statistic but included smoking status
in addition to the six variables in the primary model. Overall, the BLISS score may perform better in
predicting respiratory admissions than the scores currently available, but further research is required to
compare this model with existing ones in other data sets. Important next steps are external validation,
proposing and evaluating a model of use to guide patient management, and exploration of the best ways
to implement such a score in primary care practice.
Strengths and limitations
We used recommended and up-to-date approaches for our validation study and model development,
overcoming limitations of previous studies. Using data from a research cohort (the Birmingham primary
care COPD cohort) meant that measurements were of high quality and undertaken at prescribed time
points. However, the cohort population may not be fully generalisable to primary care because patients
with more severe disease who were housebound were excluded. Including screen-detected patients was
a strength and limitation but sensitivity analyses excluding these patients did not substantially alter the
findings. For model development, although the variable components for the score are relatively simple,
these may not be routinely collected or available, and calculation of the score requires software.
Objective (iv): to explore barriers to and enablers of participation in
physical activity among people with chronic obstructive pulmonary
disease in primary care (work package 2, published)91
Rationale
Although the majority of people with COPD who are likely to be detected through case-finding could
be offered evidence-based interventions, there are few effective interventions for those with milder
disease. One intervention that has received increasing interest is exercise. Observational studies have
reported an association between higher PA levels and lower morbidity92–94 across the full range of
COPD severity. Exercise is the cornerstone of pulmonary rehabilitation programmes (PRPs), which have
been shown to have a positive impact on COPD symptoms and prognosis.95 However, PRP provision is
limited and uptake is low.96 To better understand the motivation for PA engagement among people
with COPD in the community, we explored perceived barriers and facilitators among people with
COPD using the framework from social cognitive theory.
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What we did
A purposive sample of 26 patients (age range 50–89 years; men, n = 15) from the Birmingham COPD
cohort study, with a range of COPD severity, was recruited to participate in one of four focus groups.
Thematic analysis was undertaken to identify key concepts related to their self-efficacy beliefs.
What we found
Several barriers to and enablers of PA closely related to self-efficacy beliefs and symptom severity
were identified. The main barriers were health-related (fatigue, mobility problems, breathing issues
caused by the weather), psychological (embarrassment, fear, frustration/disappointment), attitudinal
(lack of feeling in control of their condition, disregard of PA benefits, older age perception) and
motivational. The main enabling factors were related to motivation (PA as part of caring duties,
deriving enjoyment from activity or the social aspects), attitudes (positive view of PA), self-regulation
(e.g. keeping to a routine) and performance accomplishments (sense of achievement in fulfilling
personal goals). This information can help to tailor management of people with COPD.
Strengths and limitations
The use of social cognitive theory in this study was novel, and allowed the identification of personal
barriers related to perceptions, motivation and attitudes towards physical activity, which went beyond
the external barriers identified in previous studies. This understanding can inform interventions that
have the potential to improve attendance and adherence. Furthermore, by including distinct subgroups
of patients, we identified context-specific factors, such as barriers specific to those who are in paid
employment, thereby informing the tailoring of future interventions.
However, the study participants predominantly had mild to moderate COPD and so the findings may not
reflect the views of those with more severe disease. Furthermore, the voluntary nature of participation
may have meant that the views of some who were less interested in PA were not included. The emergence
of themes may also have been influenced by the use of social cognitive theory, and potentially different
themes might have dominated had a different theoretical framework been used.
Other collaborations and analyses of cohort data
One of the aims of establishing a cohort was to allow it to become a platform for testing other
hypotheses and interventions. As a result, several groups, including postgraduate students and other
collaborators, worked with us to introduce discrete questions in some of the follow-up questionnaires
or undertook analyses from the data collected for the cohort study. The main substudies are
described below.
Cohort data used for analyses leading to a PhD thesis: Buni97
Rationale
There has long been uncertainty about the nature and prognosis of people with chronic respiratory
symptoms who do not yet meet the accepted airflow obstruction criteria for COPD.98 In 2001, the
GOLD committee included an additional ‘at-risk’ stage in the description of COPD patients with a view
to considering early interventions. Patients in this stage (known as GOLD stage 0) were thought to
be ‘at risk’ of developing COPD in the future.61 However, in 2006, GOLD stage 0 was removed from
the classification owing to a lack of supporting evidence regarding progression to diagnosed COPD.
Nevertheless, there remain many patients (particularly smokers) in the population with such symptoms;
some patients even carry a formal diagnosis of COPD and are therefore potentially ‘overdiagnosed’.
It is debated whether these patients represent a group with ‘pre-clinical’ COPD or if they have other
conditions that explain their symptoms. We undertook a range of primary and secondary data analyses
to help answer these questions.
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What we did
We undertook three linked systematic reviews to identify and assess published studies that
(1) examined the risk of developing COPD among GOLD stage 0 patients compared with the normal
population, (2) examined the prognosis of GOLD 0 patients compared with established COPD patients
and/or (3) evaluated factors that affected the prognosis of GOLD 0 patients. The primary studies
included analysis of (a) data from the 2010 Health Survey for England (HSE)99 to evaluate the independent
effect of respiratory symptoms by airflow obstruction on quality of life, (b) cross-sectional data from
the Birmingham COPD cohort study to compare the characteristics and health outcomes of GOLD
0 patients with newly diagnosed (case-found) COPD patients who had airflow obstruction and (c) cross-
sectional data from the Birmingham COPD cohort study to compare the characteristics and health
outcomes of people on the GP COPD register who did not have airflow obstruction (overdiagnosed)
with those of people who had spirometric obstruction.
What we found
The systematic reviews revealed very few published studies evaluating the prognosis of people with
GOLD 0 symptoms, and the studies that were found were heterogeneous in design, populations and
outcomes. A tentative conclusion was that those with GOLD 0 symptoms may show faster decline in
FEV1 than the normal population, but the risk of developing COPD was not consistent. Persistent
GOLD 0 symptoms may be an important predictor of development of COPD and FEV1 decline.
Persistent symptoms were associated with continued smoking and, in some studies, the presence of
metabolic syndrome. GOLD 0 patients had similar risks of mortality to GOLD 1 patients, and those
who were current smokers had similar risks to GOLD 2 patients. GOLD 0 patients often had similar
health-care use to established COPD patients.
The HSE analyses revealed a gradient of effect on quality of life from ‘normal’ to those with COPD.
Asymptomatic patients with airflow obstruction only were much more similar to ‘normals’, and those
with GOLD 0 were more similar to those with both symptoms and airflow obstruction (i.e. defined as
COPD). Dyspnoea and wheeze were more strongly associated with poor quality of life than chronic
productive cough.
Analyses of the Birmingham COPD cohort showed that GOLD 0 patients had similar consumption of
health-care resources to those newly identified with COPD, additionally indicating similar quality
of life, exercise capacity and exacerbation-like events in these two groups. GOLD 0 patients were
more likely to be female, to be obese and to have multiple comorbidities (e.g. cardiovascular disease,
hypertension, diabetes and depression) than diagnosed COPD patients, but they were not more likely
to have either diagnosed or undiagnosed asthma (assessed using GOLD/ATS definition of bronchodilator
reversibility; a change of > 12% of baseline FEV1 if this exceeds 200 ml). Overall, 10% had reversible
airflow obstruction suggestive of asthma.
Overdiagnosed COPD patients (≈14% on UK COPD registers) were also more likely to be female,
to have never smoked and to be obese (19% had restrictive pattern disease) and were slightly more
likely to have multiple comorbidities. Around 20% of these patients had spirometric abnormalities
consistent with restrictive lung disease. Their quality of life, exacerbation history, exercise capacity
and health-care utilisation were very similar to those of GOLD 0 patients.
In conclusion, the presence of respiratory symptoms is epidemiologically and clinically relevant.
GOLD 0 patients have similar poor quality of life and health-care consumption to those with mild COPD.
It is still uncertain whether this group will develop COPD or if they are ill because they have other
conditions. It is also possible that spirometric criteria for defining COPD need to be reconsidered.
Future longitudinal studies are needed to further investigate GOLD stage 0 and to inform management
guidelines that may include earlier interventions. This is important to help improve patients’ quality of
life, reduce the risk of misdiagnosis and reduce inappropriate health-care resource use.
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Collaboration with Professor Mike Thomas from the University of Southampton: Brien et al.100
This analysis explored demographic factors, lung function/COPD-related symptoms and psychosocial/
behavioural factors associated with quality-of-life impairment (using COPD CAT scores) in people
with COPD. In a multivariable model, we showed that dyspnoea, illness perception, dysfunctional
breathing symptoms and depression explained most of the impairment in quality of life. Thus, interventions
targeting psychological factors could improve outcomes in people with COPD.
Linked trial funded through the NIHR National School of Primary Care Research: Jolly et al.101
This trial was a modification of a WP in the original programme grant, with additional funding. Overall,
577 people with earlier-stage COPD (MRC dyspnoea grade 1 or 2) were recruited from general practices
(2014–15). Participants were randomised to a nurse-delivered telephone health coaching intervention
(smoking cessation, increasing PA, medication management and action-planning) or usual care. Compared
with usual care, participants in the intervention group reported significantly greater PA at 6 months.
Dickens et al.102
We obtained additional funding from the National Institute for Health Research (NIHR) School of
Primary Care Research to undertake a linked study to assess the accuracy of microspirometry as a
screening tool for undiagnosed COPD. The relevant measurements were undertaken during cohort
participants’ visits. We compared lung function measures obtained from the Vitalograph® (Vitalograph
Ltd, Buckingham, UK) lung monitor with post-bronchodilator confirmatory spirometry. We found that
the optimal cut-off point for the lung monitor was a FEV1/FEV6 of < 0.78, resulting in sensitivity of
82.8% (95% CI 78.3% to 86.7%) and specificity of 85.0% (95% CI 79.4% to 89.6%).
Cohort data used by Master of Public Health students: Khan et al.103
In this analysis, the extent of self-management behaviour and support reported by cohort participants
was described. The majority of 1078 responders reported taking medications as instructed and
receiving annual influenza vaccinations. However, only 40% had self-management plans and half
reported never having received advice on diet/exercise. Fewer than half of current smokers had been
offered help to quit in the previous year. Having a self-management plan was associated with better
medication adherence and better disease knowledge.
Cohort data used as part of a PhD thesis: Kosteli104
One chapter is dedicated to the focus groups exploring the views of COPD patients on PA.
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Work package 3: chronic obstructive
pulmonary disease and occupational
performance
Objective (i): to examine factors associated with employment (published),
absenteeism and presenteeism (published) among COPD patients of
working age (work package 3)105,106
Rationale
Among those with COPD in the UK, approximately 40% are below retirement age; of these,
25% are not able to work.107 Among those who continue to work, COPD is likely to affect work
capability through sickness absence (9% of all certified absences) and working while unwell
(presenteeism).108 Data from other countries suggest that people with COPD (including undiagnosed109
and mild disease110) have a poorer employment history and retire earlier than people with normal lung
function,111 but there were no data quantifying this in the UK, and no studies to examine presenteeism
or productivity among working adults with COPD. Indirect societal costs attributable to COPD (largely
owing to absenteeism) are high. Studies based on other conditions suggest that presenteeism costs
may exceed those associated with absenteeism.112 Few studies have examined which factors among
people with COPD are associated with lower employment and work productivity. This information
could inform future interventions, which could, in turn, improve patients’ work experience, thereby
reducing the burden and societal costs related to COPD.
What we did
We undertook cross-sectional analysis of baseline data of patients from the Birmingham COPD cohort
who were of working age. We compared the characteristics of those who were in paid employment with
those who were not. Logistic regression analysis was used to assess the effects of sociodemographic,
clinical and occupational characteristics on the likelihood of being employed. Using the subsample
in paid employment, we examined characteristics associated with absenteeism (defined by self-report
over the previous 12 months) and presenteeism (assessed using the Stanford Presenteeism Scale).
What we found
Among the 1889 people in the cohort who had COPD, 608 were of working age, of whom 248 (40.8%)
were in work. Older age (60–64 years vs. 30–49 years: OR 0.28, 95% CI 0.12 to 0.65), lower educational
level (no formal qualification vs. degree/higher level: OR 0.43, 95% CI 0.19 to 0.97), poorer prognostic
score [highest vs. lowest quartile of modified BODE score: OR 0.10, 95% CI 0.03 to 0.33] and history
of high occupational exposure to VGDF (high VGDF vs. no VGDF exposure: OR 0.32, 95% CI 0.12 to
0.85) were associated with a lower probability of being employed. Only the degree of breathlessness
component within the BODE score was significantly associated with employment. Among those who
were in paid employment, degree of breathlessness was the only factor associated with both absenteeism
(high absenteeism in severe vs. mild dyspnoea: OR 1.84, 95% CI 0.54 to 6.27; p < 0.01) and presenteeism
(working while unwell in severe vs. mild dyspnoea: OR 18.11, 95% CI 2.93 to 112.21; p < 0.01).
Additionally, increasing history of occupational exposure to VGDF was independently associated with
presenteeism (poor presenteeism in medium/high exposure vs. no exposure: OR 4.34, 95% CI 1.26 to
14.93; p < 0.01).
Based on these findings, future interventions should focus on managing breathlessness and reducing
occupational exposures to VGDF to improve work capability among those with COPD.
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Strengths and limitations
The inclusion of a wide range of patients with COPD from primary care, including case-found patients,
was novel. The assessment of occupation in detail and linking with a job exposure matrix to estimate
VGDF exposure was a strength. However, overall, the sample of participants in paid employment
was small and the wide CIs for several estimates suggest that there was insufficient power to clarify
associations. We did not have objective measures of absenteeism and some other measures were also
based on self-report, which may introduce errors.
Objective (ii): to examine how disease progression (lung function decline,
exacerbation) over time is associated with occupational performance
(employment, absenteeism and presenteeism) among chronic obstructive
pulmonary disease patients in employment (work package 3, manuscript
in preparation)
Rationale
The burden of COPD on the working population is high. The relationship between sickness and disability
and unemployment is poorly understood and could be better informed by longitudinal follow-up.
A number of factors, including sociodemographic characteristics, the general economic environment
and the severity of chronic disease, have an impact on employment and an individual’s ability to work.
We undertook longitudinal analysis to examine how disease progression is associated with occupational
outcomes, adjusting for clinical, sociodemographic, occupational and labour market factors.
What we did
We used data collected during the follow-up period for those with COPD in the Birmingham COPD
cohort study. Participants completed a series of questionnaires at baseline, providing information
on their demographics, socioeconomic circumstances, health, lifestyle and occupation. At 6-monthly
intervals they completed further questionnaires, reporting on changes in employment and, for those in
paid employment, completed questions on presenteeism and absenteeism. Trained research assistants
collected clinical information at two face-to-face assessments (baseline and the final follow-up), which
included spirometry. We undertook longitudinal analyses, including participants who were in paid
employment at baseline.
Four markers of disease progression were assessed: FEV1 (no or limited decline vs. greater decline),
number of respiratory-related hospital admissions, breathlessness (no increase vs. increase in MRC
score) and symptom impact (no increase vs. increase in CAT score).
For the primary analyses, decline in FEV1 was based on the following thresholds (comparing baseline
spirometry values with those at the final follow-up): > 113.3 ml per year in men and > 90.1 ml per year
in women. These were based on the upper limit of normal decline rates in FEV1 described in healthy
adults.113 Respiratory-related hospital admissions was calculated as the number of admissions during
the study follow-up (continuous data). The minimal clinically important difference (MCID) for the
MRC respiratory questionnaire (1-point increase)114 was used to define worsening breathlessness,
where MRC scores were compared at two time points (baseline and final follow-up for each outcome
measure). Additionally, the MCID value for the CAT score was used to define worsening symptom
impact. However, because this varies in the current literature,115 two analyses were conducted.
The primary analysis was based on an increase of < 2 or ≥ 2 points at the final follow-up.
Multivariable regression analyses were conducted to examine the effects of disease progression on
each of the outcomes, adjusting for age, sex, educational attainment, social deprivation (using the IMD
derived from participant home postcode), MRC score, GOLD staging, occupational exposure to VGDF
in current job at baseline visit (paid employment and presenteeism analyses) and number of hours
worked at baseline (absenteeism analysis).
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What we found
Among the 248 participants with COPD who were in paid employment at baseline, follow-up data
were available for 174 (70.2%). Among those who were followed up, 144 (82.8%) remained in paid
employment and 30 (17.2%) who had initially been in paid employment became unemployed. The mean
length of follow-up was 25.8 months [standard deviation (SD) 5.8 months].
Our point estimates were suggestive of an association between increasing number of respiratory-
related hospital admissions (OR 0.32, 95% CI 0.09 to 1.14; p = 0.08), decline in FEV1 (OR 0.64, 95% CI
0.11 to 3.71; p = 0.62) and worsening MRC dyspnoea score (OR 0.62, 95% CI 0.19 to 2.06; p = 0.44)
and reduced probability of remaining in paid employment, but CIs were very wide and no firm
conclusions were possible. We found no associations between worsening symptom impact (CAT score)
and reduced probability of remaining in paid employment.
Prospective absenteeism data were available for 113 (59.8%) participants, with a mean length of follow-up
of 19.5 months (SD 5.3 months). Among this group, 63 (55.8%) reported taking > 1 day off over the
follow-up period. Absenteeism ranged from 0.5 to 180.0 days per year [mean 16.3 days off per year
(SD 28.9 days off per year); median 6.0 days off per year (IQR 2.7–5.5 days off per year)]. In the total cohort
population, the mean and median days off per year were 9.0 (SD 23.0) and 1.5 (IQR 0.0–7.0), respectively.
Worsening breathlessness [incidence rate ratio (IRR) 3.06, 95% CI 1.29 to 7.26; p = 0.01] and
respiratory hospital admissions (IRR 2.01, 95% CI 1.09 to 3.69; p = 0.03) were associated with an
increased risk of sickness absence duration, and point estimates suggested that worsening symptom
impact (CAT score) might also have an effect, although CIs were wide. Associations between FEV1
decline and sickness absence duration were not observed.
Follow-up data on presenteeism were available for 163 (86.2%) participants, among whom 43 (26.4%)
had worsening presenteeism. Worsening presenteeism was significantly associated with worsening CAT
score (OR 5.74, 95% CI 1.18 to 27.83; p = 0.03) and may be associated with worsening MRC dyspnoea
score (OR 2.25, 95% CI 0.76 to 6.68; p = 0.14). No strong evidence of any patterns were observed
between FEV1 decline or respiratory-related admissions and worsening presenteeism.
In summary, disease progression, characterised by a greater number of respiratory hospital admissions
(proxy for severe exacerbations) and worsening symptoms, may be associated with poorer work
productivity. We did not find any associations between physiological decline, measured by increase
in airflow obstruction, and occupational outcomes. Given the wide CIs, further research is needed to
increase power to detect genuine associations.
Strengths and limitations
Although participants were drawn from a population with a wide range of sociodemographic, clinical and
occupational characteristics, the analyses were based on a small sample size, resulting in low power and
lack of precision for many estimates. The observed associations raise hypotheses for future research
and have to be interpreted with caution. The length of follow-up (2.5 years on average) may be insufficient
for observing a decline in lung function, and cut-off points for abnormal decline are not agreed. The study
included an older working population and, therefore, a healthy worker survivor effect might apply.
Objective (iii): to assess the feasibility and benefits of offering formal
occupational health assessment and subsequent recommendations aimed
at improving work-based indices to people with chronic obstructive
pulmonary disease in employment (work package 3, published PhD thesis)116
Rationale
A UK government report focused on the need to support individuals of working age to remain in
or to return to employment from sickness absence.117 The report made a number of recommendations,
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including the need for early workplace interventions, improved access to OH services and changes in
sickness certification from ‘sick’ to ‘fit’ notes.118 The feasibility and effectiveness of early workplace
interventions to support people with COPD with poor work performance has not been assessed.
What we did
Within the Birmingham COPD cohort, we invited all those who were in paid employment at baseline
to a tailored assessment with an OH practitioner to explore and identify workplace factors that might
negatively affect their work performance or exacerbate their condition, and to recommend appropriate
modifications. Participants’ self-management practices were also assessed. Recommendations were
sent to the participant and, with their permission, to their GP and their employer. We examined
acceptability (uptake of intervention and recommendations and exploration of participant views) and
feasibility (proportion with recommendations and uptake) of the intervention.
What we found
Only 35 (11.3%) eligible patients agreed to take part; 109 (35.3%) declined and 153 (49.5%) did not
respond. The main reasons for declining to take part included perceived lack of need (n = 54; 49.5%),
had already made workplace adjustments (n = 8; 7.3%) and concern about employer involvement (n = 5;
4.6%). Most of those who took part (n = 28; 80.0%) required at least one OH recommendation and all
required and received self-management recommendations. The most common OH recommendations
were to modify working practices and to seek advice from the workplace OH department (or GP for
those with limited access to OH services) about their respiratory symptoms in the work environment.
However, only 28 out of 75 (37.3%) recommendations were reported as implementable by the
interviewed participants.
Overall, the very low uptake rates for the intervention and low implementation of recommendations
suggest that, in its current format, this is not a worthwhile intervention. In particular, participants were
hesitant about employer involvement. Nevertheless, the finding that modifiable workplace adaptations
and self-management actions were identified for almost all participants suggests that there may be
benefit from such assessments to be undertaken in a different context.
Strengths and limitations
Although this was a novel intervention, the main limitation was the small sample size. Therefore, any
patterns assessed among those who received recommendations should be interpreted with caution.
Although the absence of randomisation and a control group makes it difficult to draw conclusions
about the impact of the intervention on patients, the purpose was to explore feasibility. It was not
possible to involve any employers in the study. Therefore, uptake of recommendations from the
employer’s perspective is unknown.
Additional outputs and published analyses related to work
package objectives
l Rai,116 shortlisted for the British Thoracic Society Early Career Investigator of the Year award
(2013), with a ‘highly commended’ prize award.
l Rai et al.119 This systematic review (based on 44 studies published from 1937 to 2017) summarised
the effects of COPD on employment and work productivity. The main findings were that people
with COPD were less likely to be in paid employment than similar counterparts without COPD.
There was also some evidence of poorer work productivity among people with COPD, although
relatively few studies had examined the effect of disease on presenteeism. The limitations in the
current evidence were highlighted, with recommendations for future research.
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Patient and public involvement
Patient advisory group
Patient involvement has been a central part of this programme from the planning stage. From the start,
we involved a patient with COPD (Michael Darby) who was the former chairperson of the Birmingham
‘Breathe Easy’ patient group and has advised on previous research studies. In discussion with him, we
planned to set up a small panel of patients [the patient advisory group (PAG)] chaired by MD. MD was
also invited to the external programme steering committee meetings and wider investigator meetings.
Prior to submission of the proposal, MD contributed to the programme plans by advising on the
following aspects:
l the need for clear and simple patient information leaflets, with a suggestion that these are read
through and commented on by the PAG
l the potential problem of incomplete response rates to mailed questionnaires and the suggestion of
obtaining data through additional sources if possible (leading to us supplementing data collection by
use of EHRs)
l highlighting potential ill health among the PAG and suggesting a deputy chairperson to support
the role.
The PAG was formed once the programme started and five individuals with COPD were appointed.
Over the course of the programme, the group met five times, with additional support in between to
comment on documents and meetings with other researchers to discuss new project ideas. Each
meeting was attended by at least three PAG members and lasted for around 2 to 3 hours. A charter
with terms of reference was drawn up and agreed, and PAG members were provided with some initial
training at the first meeting.
The PAG provided input to the following aspects of the programme:
l commenting on and modifying wording for the patient information leaflets
l suggestions for improving the wording and flow of questionnaires and how these were grouped
l piloting completion of questionnaires to provide an estimate of timing
l piloting the patient assessment process and advising on how to organise the assessments
l advising on practical issues that patients would face when attending assessments and how to
support patient attendance
l ensuring that we included an opt-out process for patients who may not want their data accessed
through the practice as part of the TargetCOPD follow-up study.
At each meeting, PAG members received an update on the programme and the findings so far and had
an opportunity to reflect and comment. Mostly, this resulted in general approval and support of the
findings, with no modifications.
The PAG has been consulted about the dissemination of findings and has suggested that an opportunity
to invite patients to an open evening with interesting speakers, reports on the findings and a social
element (preferably in spring) would be welcome.
Multistory
During the course of the programme we were approached by an arts-based charity, Multistory
(URL: https://multistory.org.uk; accessed 31 August), who had commissioned an artist to undertake
a project (Black Country Lungs) to describe the story of people with COPD in the Black Country.120
The charity approached us based on the BLISS research programme from a website search. They used
a discussion on the various themes in the programme and our findings as a basis for exploring ideas
with patients who took part in their project.
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In addition to their main exhibition, a preview of artwork was displayed at the University of Birmingham
Science and Art Exhibition, where members of the public and participants from our research study were
invited. Our research group was involved in a panel discussion at which we summarised the findings from
our programme.121
Conclusions and research recommendations
Screening for undiagnosed chronic obstructive pulmonary disease
Underdiagnosis of COPD is well recognised worldwide, with at least half of patients thought to be
undiagnosed.122 Although there is some evidence that, overall, these individuals consume health
services to an equivalent degree to those with diagnosed disease,123 there is insufficient evidence
that screening for undiagnosed COPD is worthwhile.46,124,125 One common uncertainty is the lack of
trial evidence that the early identification of COPD leads to clinical benefits.
Our systematic reviews of studies of case-finding have shown that targeting screening to a higher-risk
group is important126 and identified which of the currently tested screening strategies is/are most
effective in increasing yield.51 The TargetCOPD trial demonstrated that case-finding for undiagnosed
COPD is a cost-effective process for increasing the number of new COPD cases identified with much
higher yield than routine practice, particularly if using an active, targeted approach.21 Furthermore,
we have used data from the trial to develop alternative algorithms for case-finding that may improve
the efficiency of the process further by reducing the number needed to screen.49
The majority of newly identified cases in the TargetCOPD trial had potential to benefit from
evidence-based recommended treatments. Using the best available evidence from the literature for
our assumptions, our economic model demonstrated that a systematic, 3-yearly screening programme
is likely to be cost-effective, with favourable cost/QALY gained in all scenarios (paper under review).
We also found that case-finding was generally acceptable to patients42 and primary care staff,43
although a lack of awareness in relation to symptoms (among patients) and approaches to effective
management of early disease (among health-care staff), as well as limited resources to deal with
increasing numbers of people with COPD, were highlighted by both groups.
Longer-term follow-up of patients who were case-found through our trial demonstrated that just
over one in five were added to the practice COPD register and, even among these patients, guideline-
recommended management was rarely administered. This may be related to the concerns raised in our
qualitative study around low awareness of management of early COPD, lack of resources and perceived
lack of effective strategies.
After 4 years’ follow-up, we demonstrated no evidence that screening had an effect on clinical outcomes.
Hospitalisation and mortality rates did not significantly differ between patients in the case-finding or
routine care practices. Although respiratory hospitalisation rates were significantly higher in the active
than in the opportunistic case-finding arm, there was no significant difference between groups in overall
hospitalisation or mortality. This may be related to more hospitalisations being attributed to a respiratory
cause in these patients who had a COPD diagnosis.
This finding may seem to contrast with the findings from our Markov model, which suggest that
estimates of cost-effectiveness are robust as long as 8% of screen-detected patients are optimally
treated. However, considering the small number of case-found patients added to the COPD register,
the low levels of implementation of treatment and the probably reduced benefits of such treatment
among more mildly affected patients could take the effective benefit of case-finding in our patient
population below 8%.
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Implications for screening
The lack of observed effects of case-finding on clinical outcomes in our trial could be related to a number
of factors. First, we had a very low level of uptake of screening overall. Less than 40% of eligible patients
responded to the initial screening questionnaire. Low levels of awareness of symptoms, lack of perceived
susceptibility, fear of screening or greater importance being attached to competing comorbidities may
explain this. Further research is needed to identify approaches for increasing uptake if a population
screening programme is to be implemented.
Second, we found poor management of screen-detected COPD cases, with relatively few of them
being added to the practice COPD register, with subsequent reviews and initiation of evidence-based
interventions. Interviews with primary health-care staff around perceptions of screening highlighted
fears around workload implications and overdiagnosis and the need for better training on how to
manage screen-detected COPD. Further research should focus on the development and evaluation
of pathways of care for screen-detected COPD cases. Furthermore, there is a need for prioritisation
of resources to increase the capacity of primary care staff to deal with an influx of new COPD cases
and the development of training programmes to support better management of people with COPD.
Third, we assumed that screen-detected COPD patients are the same as clinically diagnosed patients,
with similar natural history of disease and with the same response to interventions. This assumption
needs to be tested in future research. Follow-up of case-found patients is important to understand
disease progression better over time. Furthermore, clinical trials should test the effectiveness of current
therapies in case-found populations to assess whether or not they are as effective in these patients.
Overall, our findings are in keeping with the recommendations by the UK National Screening Committee43,44
and the USPSTF45 that screening for undiagnosed COPD should not currently be implemented. The
research recommended above will help support future decision-making. Although in this report, and in
common with many respiratory researchers, we frequently use the word ‘case-finding’, where case-finding
is undertaken in a systematic way it is a form of screening and, therefore, should be subject to the same
criteria before being implemented.
Multidimensional prognostic model for chronic obstructive pulmonary disease
People with COPD have high risk of respiratory infections resulting in hospitalisation and also a higher
risk of premature mortality than those without COPD. However, COPD is heterogeneous and not all
patients progress in the same way. Traditionally, lung function has been used to grade COPD severity, but
there is increasing evidence that prognosis is determined by an inter-related set of factors, which has led
to the development of multidimensional prognostic models.127 Existing models have predominantly been
developed in secondary care populations and are mainly developed to predict mortality risk; few have
been developed using high-quality statistical approaches or been externally validated, and they often
do not perform better than measures of lung function alone.78,127,128 The most recent NICE guidelines31
highlight the need for prognostic tools that are validated in UK primary care COPD populations and that
examine outcomes wider than just mortality.
We externally validated the ADO score, which was identified as the most discriminatory for 3-year
mortality in a systematic review, in a UK primary care population.78 Although we found that it has
promising discrimination, the model needs to be recalibrated if used to predict risk of mortality within
1 to 2 years.
We also developed a new prognostic index to predict 2-year risk of hospitalisation for people with
COPD in primary care. Our new BLISS model, which includes variables that are easily available in
primary care settings, has promising discrimination and was adjusted for overfitting to help ensure
calibration is more reliable in case-found individuals.
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Further work is needed to externally validate the BLISS prognostic index. Further research is also
needed to evaluate the use of the index to classify people with COPD into higher- and lower-risk
groups to aid management decisions.
Occupational outcomes in chronic obstructive pulmonary disease
A high proportion of people with COPD are of working age, but they have poorer rates of employment
and poor work productivity compared with those without COPD. To our knowledge, this was the first
study to examine which factors are associated with occupational outcomes among people with COPD.
We found that increasing breathlessness, disease progression (increasing number of respiratory hospital
admissions rather than lung function decline) and greater occupational exposure to VGDF were associated
with poorer work productivity. These disease-related factors were more likely to be associated with
poor work productivity than sociodemographic and lifestyle factors. Our findings suggest that there
may be a continuum from presenteeism to absenteeism to loss of employment.
Although our OH-focused intervention was not feasible, modifiable workplace adaptations and
self-management actions were identified for almost all participants, suggesting possible benefit from
such assessments in a different context.
Further research is needed to examine how presenteeism and absenteeism are related to better
understand presenteeism in relation to health and to assess whether or not interventions to modify
the course of COPD have an impact on occupational outcomes.
Summary of research recommendations
Screening
1. Development and evaluation of interventions to better implement effective treatments for COPD in
primary care, including pathways to manage case-found COPD.
2. Evaluation of existing interventions in case-found COPD to determine if the interventions have
similar effectiveness.
3. Long-term follow-up of TargetCOPD participants to establish whether or not clinical benefits might
occur, given that people with case-found disease had milder symptoms and better lung function
than those already on GP practice COPD registers. Development and evaluation of approaches for
increasing uptake of invitation for screening for undiagnosed COPD.
4. Development of more efficient approaches to case-finding and identifying which screening test or
strategy has the best performance (in terms of sensitivity and specificity).
5. Development and evaluation of different models for delivery of quality-assured diagnostic spirometry
screening services, considering workforce implications and how this could be incorporated into the
new early diagnostic hubs for primary care networks proposed in the long-term plan.
Prognosis
6. Description of natural history and prognosis of case-found patients and those with indicative
symptoms but normal lung function, describing any heterogeneity, and establishing whether or not
there are phenotypic characteristics that are associated with progression.
7. Exploration of how prognostic models might be used by primary care staff in managing
COPD patients.
8. Evaluation of the BLISS prognostic model in directing patient management.
9. Validation of the BLISS case-finding algorithm.
10. External validation of the impact of the BLISS prognostic model.
11. Consideration of the development of new prognostic scores for primary care COPD patients that
predict all-cause (rather than respiratory) hospitalisation, given the multimorbid nature of the condition.
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Work-related impacts
12. Examination of the relationship between presenteeism and absenteeism and whether or not
presenteeism has an impact on health-related outcomes.
13. Development and evaluation of interventions to reduce dyspnoea and VGDF exposure in
occupational outcomes in people with COPD.
14. Codevelopment and evaluation of an OH intervention to improve work productivity among people
with COPD who are in paid employment.
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The BLISS programme research costs were funded by the NIHR Programme Grants for AppliedResearch programme. Recruitment for the TargetCOPD trial was supported by the Clinical
Research Network.
The co-investigator team (Peymané Adab, Rachel Jordan, David Fitzmaurice, Jon Ayres, KK Cheng,
Brendan Cooper, Amanda Daley, Sheila Greenfield, Kate Jolly, Sue Jowett, Martin Miller, Richard Riley,
Stanley Siebert, Robert Stockley and Alice Turner) met 6-monthly to review progress and advise on
aspects of the programme.
The programme management group (Peymané Adab, Rachel Jordan, David Fitzmaurice, Alexandra Enocson
and Andrew Dickens) met weekly to oversee programme progress, with contributions from other
co-investigators and researchers at different stages of the programme. In addition to specific contributions
outlined below, all authors have contributed to drafting or revising sections of this report and have
approved the final submitted version.
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on aspects of questionnaire design and PA assessment.
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final report.
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the findings.
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Appendix 2 Screening questionnaire for
TargetCOPD trial
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